var title_f24_30_25056="Splinter hemorrhage trichinosis";
var content_f24_30_25056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subungual splinter hemorrhages",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subungual splinter hemorrhages in a patient with T. papuae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Weller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25056=[""].join("\n");
var outline_f24_30_25056=null;
var title_f24_30_25057="Closed reduction for posterior sternoclavicular dislocation";
var content_f24_30_25057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Closed reduction for posterior sternoclavicular dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 455px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Technique for closed reduction of the SC joint.",
"    <br/>",
"    (A) The patient is positioned supine with a sandbag placed between the two shoulders. Traction is then applied to the arm against countertraction in an abducted and slightly extended position. In anterior dislocations, direct pressure over the medial end of the clavicle may reduce the joint.",
"    <br/>",
"    (B) In addition to the traction, it may be necessary to manipulate the medial end of the clavicle with the fingers to dislodge the clavicle from behind the manubrium.",
"    <br/>",
"    (C) In stubborn posterior dislocations, it may be necessary to sterilely prepare the medial end of the clavicle and use a towel clip to grasp around the medial clavicle to lift it back into position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dutta AK, Wirth MA, Rockwood CA. Sternoclavicular joint injuries. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Torneta III P (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25057=[""].join("\n");
var outline_f24_30_25057=null;
var title_f24_30_25058="Supine dumbell flies";
var content_f24_30_25058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Safe and unsafe range of motion for supine dumbell flies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure A depicts the appropriate and safe range of motion for a supine dumbell fly, with the upper arm parallel to the ground. Figure B depicts a supine dumbell fly with an increased range of motion, increasing the risk of soft tissue injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Pat Vehrs, PhD, FACSM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25058=[""].join("\n");
var outline_f24_30_25058=null;
var title_f24_30_25059="Hypothalamic-pituitary axis";
var content_f24_30_25059=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypothalamic-pituitary axis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25059/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25059/contributors\">",
"     Corrine K Welt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25059/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25059/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25059/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25059/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/30/25059/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothalamus can be considered the coordinating center of the endocrine system. It consolidates signals derived from upper cortical inputs, autonomic function, environmental cues such as light and temperature, and peripheral endocrine feedback. In turn, the hypothalamus delivers precise signals to the pituitary gland which then releases hormones that influence most endocrine systems in the body. Specifically, the hypothalamic-pituitary axis directly affects the functions of the thyroid gland, the adrenal gland, and the gonads, as well as influencing growth, milk production, and water balance (",
"    <a class=\"graphic graphic_table graphicRef53814 \" href=\"UTD.htm?6/3/6204\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25059/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothalamic-pituitary axis will be reviewed here. The functions of the hypothalamic and pituitary hormones are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6857?source=see_link\">",
"     \"Physiology of corticotropin-releasing hormone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43030?source=see_link\">",
"     \"Physiology of growth hormone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10200?source=see_link\">",
"     \"Thyroid hormone action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hypothalamus is also involved in several important nonendocrine functions such as temperature regulation, the activity of the autonomic nervous system, and control of appetite.",
"   </p>",
"   <p>",
"    The anatomy and unique blood supply of the hypothalamic-pituitary axis are essential to its function. The hypothalamic hormones are small peptides that are generally active only at the relatively high concentrations achieved in the pituitary portal blood system. Their small size and lack of known binding proteins results in rapid degradation and very low concentrations in the peripheral circulation. However, ectopic production of several of these hormones has been identified, both by normal white blood cells and by chromaffin cell tumors. Peripheral hormone receptors have also been identified, although their physiologic importance is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothalamus is located at the base of the brain, below the third ventricle and just above the optic chiasm and pituitary gland (",
"    <a class=\"graphic graphic_figure graphicRef71164 \" href=\"UTD.htm?16/57/17297\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25059/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This location can be thought of as the intersection of the cortex, the cerebellum, and the brainstem. Most of the cell bodies of the small neurons containing hypothalamic releasing hormones are located in the tuberal area in the anterior part of the hypothalamus. Afferent pathways to the hypothalamic nuclei arise from the brainstem, thalamus, basal ganglia, cerebral cortex, and olfactory areas. Efferent pathways include the dorsal longitudinal fasciculus connecting the hypothalamus to the brainstem reticular centers, connections to the autonomic nervous system and the thalamus, and the hypothalamo-neurohypophysial tract which connects the paraventricular and supraoptic nuclei, which produce antidiuretic hormone, to nerve terminals in the median eminence and to the posterior pituitary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pituitary stalk, which connects the median eminence to the pituitary gland (",
"    <a class=\"graphic graphic_figure graphicRef62576 \" href=\"UTD.htm?43/41/44689\">",
"     figure 2",
"    </a>",
"    ), passes through an opening in the dura surrounding the brain. The pituitary gland lies outside the dura. It rests in the sella turcica below the optic chiasm and is divided into anterior and posterior portions, each with distinct embryology, anatomy, and function. The anterior pituitary (or adenohypophysis) arises from Rathke's pouch from the oral cavity, and the posterior pituitary (or neurohypophysis) arises from neural ectoderm at the floor of the forebrain. The pituitary lies almost directly behind the area between the eyes and can be accessed surgically through the back of the nose (the sphenoid bone). It is a distinctly visible structure on MRI scanning (",
"    <a class=\"graphic graphic_figure graphicRef62576 \" href=\"UTD.htm?43/41/44689\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BLOOD SUPPLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most hormones circulate systemically and therefore contact all body tissues, the hypothalamic hormones have a special circulation so that they reach their target cells in the pituitary in high concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypothalamus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminals of the hypothalamic neurons are in the median eminence, where hormones are released directly into a primary capillary plexus. These capillaries empty into the portal venous circulation, travel down the pituitary stalk, and bathe the anterior pituitary gland in a secondary capillary plexus (",
"    <a class=\"graphic graphic_figure graphicRef77878 \" href=\"UTD.htm?37/59/38834\">",
"     figure 3",
"    </a>",
"    ). Thus, the hormones released by the hypothalamic neurons reach their target cells rapidly and in high concentrations before being diluted in peripheral blood. This proximity is crucial for preservation of the pulsatile output of hormones from the hypothalamic neurons. The effect of gonadotropin-releasing hormone (GnRH), as an example, is critically dependent upon its pulsatile release. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anterior pituitary gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior pituitary lacks a major direct arterial blood supply; it is bathed in a dense capillary network of pituitary portal blood containing both hypothalamic hormones released in the median eminence and the hormones and paracrine and autocrine factors released from the pituitary cells themselves (",
"    <a class=\"graphic graphic_figure graphicRef77878 \" href=\"UTD.htm?37/59/38834\">",
"     figure 3",
"    </a>",
"    ). The venous plexus empties into the petrosal sinuses and then into the peripheral circulation via the internal jugular veins. Thus, venous blood in the petrosal sinuses has a relatively high concentration of pituitary hormones and is a useful site to catheterize and sample when assessing pituitary function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Posterior pituitary gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the anterior pituitary, which does not have nerve terminals, the posterior pituitary contains the axons and nerve terminals of larger neurons that originate in the paraventricular and supraoptic nuclei of the hypothalamus. The posterior pituitary is supplied by the inferior hypophyseal artery and drains into the inferior hypophyseal veins where its products, vasopressin and oxytocin, are released directly into the systemic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECTS OF PITUITARY STALK SECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;These anatomic relationships explain the different results of destruction of the pituitary stalk on anterior and posterior pituitary function. Because the pituitary stalk contains the axons of the posterior pituitary neurons, stalk section leads to atrophy and loss of neuron function and therefore loss of posterior pituitary hormones. In contrast, the anterior pituitary, although deprived of blood from the median eminence, continues to receive some arterial input from the inferior hypophyseal artery and therefore can maintain viability and continue to respond to hypothalamic hormones if high enough concentrations are achieved in peripheral blood.",
"   </p>",
"   <p>",
"    Serum prolactin concentrations increase after pituitary stalk division because the lactotrophs in the anterior pituitary no longer receive inhibitory signals from the hypothalamus. This phenomenon accounts for the hyperprolactinemia that often is present in patients with non-prolactin producing tumors that compress the pituitary stalk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29559209\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothalamus can be considered the coordinating center of the endocrine system. It consolidates signals derived from upper cortical inputs, autonomic function, environmental cues such as light and temperature, and peripheral endocrine feedback. In turn, the hypothalamus delivers precise signals to the pituitary gland which then releases hormones that influence most endocrine systems in the body. Specifically, the hypothalamic-pituitary axis directly affects the functions of the thyroid gland, the adrenal gland, and the gonads, as well as influencing growth, milk production, and water balance.",
"   </p>",
"   <p>",
"    The hypothalamus is located at the base of the brain, below the third ventricle and just above the optic chiasm and pituitary gland (",
"    <a class=\"graphic graphic_figure graphicRef71164 \" href=\"UTD.htm?16/57/17297\">",
"     figure 1",
"    </a>",
"    ). The pituitary stalk, which connects the median eminence to the pituitary gland (",
"    <a class=\"graphic graphic_figure graphicRef62576 \" href=\"UTD.htm?43/41/44689\">",
"     figure 2",
"    </a>",
"    ), passes through an opening in the dura surrounding the brain. The pituitary gland lies outside the dura. It rests in the sella turcica below the optic chiasm and is divided into anterior and posterior portions. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although most hormones circulate systemically and therefore contact all body tissues, the hypothalamic hormones have a special circulation so that they reach their target cells in the pituitary in high concentrations (",
"    <a class=\"graphic graphic_figure graphicRef77878 \" href=\"UTD.htm?37/59/38834\">",
"     figure 3",
"    </a>",
"    ). The blood supply of the hypothalamus, anterior pituitary and posterior pituitary are discussed above.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25059/abstract/1\">",
"      Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25059/abstract/2\">",
"      Krieger DT, Martin JB. Brain peptides (first of two parts). N Engl J Med 1981; 304:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25059/abstract/3\">",
"      Krieger DT, Martin JB. Brain peptides (second of two parts). N Engl J Med 1981; 304:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25059/abstract/4\">",
"      Krieger DT. Brain peptides: what, where, and why? Science 1983; 222:975.",
"     </a>",
"    </li>",
"    <li>",
"     Krieger DT. The hypothalamus and neuroendocrine pathology. In: Neuroendocrinology, Krieger DT, Hughes JC (Eds), Sinauer Associates, Sunderland, MA 1980. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25059/abstract/6\">",
"      Braak H, Braak E. Anatomy of the human hypothalamus (chiasmatic and tuberal region). Prog Brain Res 1992; 93:3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6628 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25059=[""].join("\n");
var outline_f24_30_25059=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29559209\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BLOOD SUPPLY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypothalamus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anterior pituitary gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Posterior pituitary gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECTS OF PITUITARY STALK SECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29559209\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6628|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/57/17297\" title=\"figure 1\">",
"      Anatomy of hypothalamus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/41/44689\" title=\"figure 2\">",
"      Hypothalamic pituitary axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/59/38834\" title=\"figure 3\">",
"      Hypothalamic blood supply",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/3/6204\" title=\"table 1\">",
"      Hypothalamic hormones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6857?source=related_link\">",
"      Physiology of corticotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43030?source=related_link\">",
"      Physiology of growth hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10200?source=related_link\">",
"      Thyroid hormone action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_30_25060="Disulfiram: Patient drug information";
var content_f24_30_25060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Disulfiram: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     see \"Disulfiram: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antabuse&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug for at least 12 hours after drinking beer, wine, or mixed drinks or taking drugs that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you stop drinking alcohol.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to disulfiram or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Heart disease or schizophrenia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink beer, wine, or mixed drinks or take any drugs that have alcohol.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks and drugs or food with alcohol in them. Avoid alcohol for 2 weeks after disulfiram is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug for at least 12 hours after drinking beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12390 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-E769C354BE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25060=[""].join("\n");
var outline_f24_30_25060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161760\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027023\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027025\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027024\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027029\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027030\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027032\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027027\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027028\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027033\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027034\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=related_link\">",
"      Disulfiram: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_30_25061="Retracted TBNA needle position";
var content_f24_30_25061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Position of the needle prior to TBNA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Correct position of the metal needle prior to TBNA: the entire beveled end is placed inside the metal hub. (B) Incorrect position of the metal needle: the sharp end of the needle is extending beyond the metal hub, and can potentially lacerate the working channel of the bronchoscope. (C and D) Incorrect position of the metal needle: the needle is placed too proximal to the metal hub and can perforate its own plastic catheter during forward thrust and potentially damage the working channel of the bronchoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25061=[""].join("\n");
var outline_f24_30_25061=null;
var title_f24_30_25062="Management of cancer treatment-induced diarrhea";
var content_f24_30_25062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 601px\">",
"   <div class=\"ttl\">",
"    Management of cancer treatment-induced diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 581px; height: 786px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; CID: chemotherapy-induced diarrhea; CTCAE: NCI Common Terminology Criteria for Adverse Events; RT: radiotherapy; IV: intravenous; SC subcutaneous; tid: three times per day.",
"     <br>",
"      * For RT-induced cases and select patients with CID, consider intensive outpatient management, unless the patient has sepsis, fever, or neutropenia.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Onc 2004; 22:2918. Copyright &copy; 2004 American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25062=[""].join("\n");
var outline_f24_30_25062=null;
var title_f24_30_25063="NSCLC malig pl eff";
var content_f24_30_25063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81680%7EPULM%2F56176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81680%7EPULM%2F56176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large pleural effusion in a 60-year-old man cytologically positive for adenocarcinoma consistent with lung primary.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image of the effusion following thoracentesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25063=[""].join("\n");
var outline_f24_30_25063=null;
var title_f24_30_25064="Pathogenetic mechanisms in primary myelofibrosis";
var content_f24_30_25064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenetic mechanisms in primary myelofibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25064/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25064/contributors\">",
"     Ayalew Tefferi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25064/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25064/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25064/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/30/25064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary myelofibrosis (PMF) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], called chronic idiopathic myelofibrosis in the 2001 WHO classification [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/3\">",
"     3",
"    </a>",
"    ], and also known as agnogenic myeloid metaplasia, is one of the chronic myeloproliferative neoplasms, which are collectively characterized by clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency (",
"    <a class=\"graphic graphic_figure graphicRef56283 \" href=\"UTD.htm?24/16/24835\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The primary disease process in PMF is a clonal hematopoietic stem cell disorder that results in chronic myeloproliferation and atypical megakaryocytic hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/4\">",
"     4",
"    </a>",
"    ]. The secondary process of bone marrow fibrosis (BMF) is the result of nonclonal fibroblastic proliferation and hyperactivity induced by growth factors abnormally shed from clonally expanded megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/5\">",
"     5",
"    </a>",
"    ]. BMF is the hallmark of PMF and contributes to the impaired hematopoiesis that leads to severe anemia. In addition to BMF and anemia, patients with PMF suffer from marked splenomegaly, extramedullary hematopoiesis, and severe constitutional symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential to arrest or reverse the BMF in PMF may offer an alternative approach to palliative therapy. With this goal in mind, the pathogenesis of PMF will be discussed here. The prognosis and treatment of PMF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link\">",
"     \"Prognosis and treatment of primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact cause of PMF is unknown. PMF, along with the other chronic myeloproliferative disorders, chronic myeloid leukemia, polycythemia vera, and essential thrombocythemia, is considered to arise from a somatic mutation of a pluripotent hematopoietic progenitor cell [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A defective stem cell \"niche\" within the bone marrow has been postulated for PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The occurrence of PMF has, in a minority of cases, been linked to exposure to thorium dioxide, petroleum manufacturing plants (especially toluene and benzene), and ionizing radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ]. A very high incidence of PMF has been noted in patients given thorium-based radiographic contrast material and in individuals exposed to atomic bombs at Hiroshima [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mice with a mutation of the GATA-1 transcription factor gene develop a hematologic picture similar to myelofibrosis at 15 months of age, and may represent a suitable animal model for the human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CELLULAR ABNORMALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chromosomal and other genetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 to 60 percent of patients with PMF have clonal karyotypic abnormalities at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/5,15-20\">",
"     5,15-20",
"    </a>",
"    ]. However, none of these abnormalities is specific to this disorder. The most common findings, accounting for 50 to 65 percent of the karyotypic changes, are deletion of a segment of the chromosome bearing the retinoblastoma gene (13q-), 20q-, and partial trisomy 1q (",
"    <a class=\"graphic graphic_table graphicRef53281 \" href=\"UTD.htm?13/32/13835\">",
"     table 1",
"    </a>",
"    ). Patients with these cytogenetic abnormalities are reported to have a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/15,16,21\">",
"     15,16,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our series of 884 patients with PMF, unfavorable karyotype has been one of the factors associated with reduced overall survival, and includes such changes as +8,",
"    <span class=\"nowrap\">",
"     -7/7q-,",
"    </span>",
"    i(17q),",
"    <span class=\"nowrap\">",
"     -5/5q-,",
"    </span>",
"    12p-, inv(3), and 11q23 rearrangement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/22\">",
"     22",
"    </a>",
"    ]. The detrimental effect of unfavorable karyotype was mostly attributed to monosomal karyotype or",
"    <span class=\"nowrap\">",
"     inv(3)/i(17q).",
"    </span>",
"   </p>",
"   <p>",
"    Gains of chromosome 9 or 9p have also been noted in our studies (13 percent) and those of others (50 percent), suggesting that genes on 9p may play a crucial role in the pathogenesis of PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/23\">",
"     23",
"    </a>",
"    ]. Of interest, mutations of JAK2 (Janus kinase 2), a gene found on 9p, have been found in approximately 50 percent of patients with PMF. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'JAK2 mutations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'Mutations in PV, ET, and PMF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of genetic mutations and single nucleotide polymorphisms have been identified in patients with PMF and other myeloproliferative neoplasms associated with leukemic transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. As an example, a A3669G polymorphism of the glucocorticoid receptor was found to contribute to the phenotype of excess myeloproliferation in PMF (eg, higher white blood cell count, larger spleen, higher frequency of CD34+ cells at diagnosis) and, in cooperation with the",
"    <em>",
"     JAK2",
"    </em>",
"    V617F mutation, increasing the risk of blastic transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, mutations in PMF involve primarily",
"    <em>",
"     JAK2",
"    </em>",
"    but also to a smaller extent",
"    <em>",
"     MPL",
"    </em>",
"    ,",
"    <em>",
"     LNK",
"    </em>",
"    ,",
"    <em>",
"     CBL",
"    </em>",
"    ,",
"    <em>",
"     TET2",
"    </em>",
"    ,",
"    <em>",
"     ASXL1",
"    </em>",
"    ,",
"    <em>",
"     IDH1",
"    </em>",
"    ,",
"    <em>",
"     IDH2",
"    </em>",
"    ,",
"    <em>",
"     IKZF1",
"    </em>",
"    ,",
"    <em>",
"     EZH2, DNMT3A, TP53, SF3B1",
"    </em>",
"    and",
"    <em>",
"     SFSR2",
"    </em>",
"    . None of these mutations has been consistently traced back to the ancestral clone, and their disease-initiating potential is uncertain. Some (eg,",
"    <em>",
"     JAK2",
"    </em>",
"    and",
"    <em>",
"     SF3B1",
"    </em>",
"    mutations) might contribute to specific phenotypes such as erythrocytosis and ring sideroblasts, respectively. Available data suggest inferior survival in PMF associated with nullizygosity for",
"    <em>",
"     JAK2",
"    </em>",
"    <span class=\"nowrap\">",
"     46/1",
"    </span>",
"    haplotype, low",
"    <em>",
"     JAK2",
"    </em>",
"    V617F allele burden, and the presence of",
"    <em>",
"     IDH, ASXL1, SRSF2",
"    </em>",
"    or",
"    <em>",
"     EZH2",
"    </em>",
"    mutations. Some of these mutations (eg,",
"    <em>",
"     IDH",
"    </em>",
"    ,",
"    <em>",
"     SRSF2",
"    </em>",
"    ) have also been associated with inferior leukemia-free survival. In contrast, the presence or absence of",
"    <em>",
"     JAK2",
"    </em>",
"    V617F,",
"    <em>",
"     MPL",
"    </em>",
"    or",
"    <em>",
"     TET2",
"    </em>",
"    mutations do not appear to affect survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12005307\">",
"    <span class=\"h2\">",
"     Cytokine abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroblasts do not share the chromosomal abnormalities found in hematopoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/30\">",
"     30",
"    </a>",
"    ]. As a result, it is thought that bone marrow fibrosis, as well as many of the other signs and symptoms of PMF, are secondary reactions to the clonal hemopathy mediated by cytokines released from the neoplastic megakaryocytes and other clonally expanded hematopoietic cells, such as T and B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link&amp;anchor=H12714880#H12714880\">",
"     \"Prognosis and treatment of primary myelofibrosis\", section on 'Elevated cytokine levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Spontaneous hematopoietic colony growth in vitro",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the hallmarks of polycythemia vera (PV) is in vitro erythropoietin- independent growth of red blood cell (RBC) colonies. Spontaneous growth of both RBC colonies and megakaryocytes (in the absence of exogenous cytokines) has also been described in a minority of patients with PMF and ET.",
"   </p>",
"   <p>",
"    A number of findings support the involvement of the trophic hormone thrombopoietin (TPO)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its receptor (c-Mpl) in the pathogenesis of PMF, particularly in the pathogenesis of bone marrow fibrosis (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Bone marrow fibrosis'",
"    </a>",
"    below). There is also evidence that the TPO system is involved in the spontaneous megakaryocyte growth in PMF. As examples, both preparations of the soluble murine TPO receptor and antisense oligonucleotides against the TPO receptor markedly inhibit spontaneous megakaryocyte growth in PMF and in ET and PV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     JAK/STAT pathway",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     JAK2 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;One suggested mechanism of intrinsic growth factor hypersensitivity in PMF involves megakaryocyte overexpression of FKBP51 associated with",
"    <span class=\"nowrap\">",
"     JAK2/STAT5",
"    </span>",
"    activation, consistent with the discovery of an activation mutation of JAK2 in patients with PV, ET, and PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'Mutations in PV, ET, and PMF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H26#H26\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'JAK2 (JAK2V617F) mutation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Constitutive activation of the",
"    <span class=\"nowrap\">",
"     JAK/STAT",
"    </span>",
"    pathway appears to be an important pathogenetic event in patients with the myeloproliferative disorders. However, only approximately 50 percent of patients with PMF have the JAK2 mutation, suggesting the presence of other modes of",
"    <span class=\"nowrap\">",
"     JAK/STAT",
"    </span>",
"    activation, such as activating mutations in hematopoietic-specific cytokine receptors (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     MPL mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of the thrombopoietin receptor (MPL) are also capable of activation of",
"    <span class=\"nowrap\">",
"     JAK/STAT",
"    </span>",
"    signaling in patients with PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/35\">",
"     35",
"    </a>",
"    ]. The finding of novel somatic activating mutations in the thrombopoietin receptor (MPL mutations W515L and W515K) in approximately 5 percent of patients with PMF, 1 percent of those with ET, and in none of the patients with PV suggests that these MPL mutations favor megakaryocyte fate while the JAK2 mutation favors erythroid fate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     BONE MARROW FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow fibrosis (BMF) in PMF results from the abnormal deposition of excess collagen derived from fibroblasts. Although several types of collagen provide the reticular matrix support in normal bone marrow, types III, IV, and I are the major components of BMF associated with PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The collagen-producing fibroblasts in PMF are functionally and physically similar to normal fibroblasts and are polyclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. They are secondarily stimulated to proliferate and overproduce collagen by growth factors secreted by the neighboring megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Thus, BMF in PMF is a reactive process accompanying the underlying clonal stem cell disorder.",
"   </p>",
"   <p>",
"    The major megakaryocyte-derived cytokine implicated in the mediation of BMF in PMF is transforming growth factor (TGF)-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/4,43\">",
"     4,43",
"    </a>",
"    ], which may interact with thrombopoietin (",
"    <a class=\"graphic graphic_figure graphicRef56172 \" href=\"UTD.htm?19/44/20162\">",
"     figure 2",
"    </a>",
"    ). Other growth factors also may contribute to the fibrotic reaction, including platelet derived growth factor (PDGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF, FGF-2), vascular endothelial growth factor (VEGF), calmodulin, matrix metalloproteinase-9, and lysyl oxidase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/4,5,43-48\">",
"     4,5,43-48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Transforming growth factor-beta'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This fibrous reaction with abnormal accumulation of extracellular matrix components is also dependent on matrix metalloproteinases (MMP) and tissue inhibitors of MMPs (TIMP) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/49\">",
"     49",
"    </a>",
"    ]. In a study of 25 patients with PMF, significantly decreased plasma levels of MMP-3 were found, which correlated inversely with the degree of bone marrow fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/50\">",
"     50",
"    </a>",
"    ]. Elevated levels of TIMP-1 were also found, suggesting that the balance between MMPs and TIMP may be essential in fibrosis formation.",
"   </p>",
"   <p>",
"    It has been suggested, based upon a murine model and on bone marrow samples from patients with PMF, that there is a significant degree of entry of hematopoietic cells into megakaryocyte cytoplasm, a phenomenon called emperipolesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/51\">",
"     51",
"    </a>",
"    ]. This is probably brought about by increased expression and abnormal localization of P-selectin by the megakaryocytes, leading to engulfment, activation, and damage to the cells, mainly neutrophils and eosinophils, passing through the megakaryocyte cytoplasm. The result is release of lytic granules from the engulfed cells, progressive destruction of megakaryocytes with degradation and lysis of their alpha granules, and release of growth factors, resulting in the marked fibroblast activation and infiltration characteristic of PMF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transforming growth factor-beta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major megakaryocyte-derived cytokine implicated in the mediation of BMF in PMF is transforming growth factor (TGF)-beta, which may interact with thrombopoietin (",
"    <a class=\"graphic graphic_figure graphicRef56172 \" href=\"UTD.htm?19/44/20162\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/44,52-57\">",
"     44,52-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TGF-beta is a glycoprotein that is synthesized and secreted primarily by the monocyte-macrophage system and endothelial cells, and also by megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/4,52,53\">",
"     4,52,53",
"    </a>",
"    ]. It is capable of enhancing the production and secretion of extracellular matrix proteins, including collagen types III and I from fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], and may also interact with IL-1, fibronectin, and substance P [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/58\">",
"     58",
"    </a>",
"    ]. The expression of TGF-beta has been demonstrated at the level of mRNA and secreted peptide in clonal megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/52,56\">",
"     52,56",
"    </a>",
"    ]. In addition, circulating concentrations of TGF-beta are increased in patients with PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro, anti-TGF-beta antibodies decrease the collagen synthesis mediated by megakaryoblast-conditioned media [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/52\">",
"     52",
"    </a>",
"    ]. This type of inhibition can also be achieved by tumor necrosis factor-alpha and interferon-gamma, which suppress the activation of type I collagen gene expression by TGF-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thrombopoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A PMF-like syndrome can be induced in mice via exposure to high concentrations of thrombopoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/60-65\">",
"     60-65",
"    </a>",
"    ]. Thrombopoietin (TPO) is the major growth factor required for megakaryocyte growth and development. The TPO glycoprotein can be modified by deglycosylation and subsequent coupling to polyethylene glycol (PEG) to be less immunogenic and have an extended half-life.",
"   </p>",
"   <p>",
"    Mice injected daily with high doses of PEG-TPO develop a reversible bone marrow fibrosis accompanied by thrombocytosis, megakaryocytic hyperplasia, splenomegaly, extramedullary hematopoiesis, and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/61,63\">",
"     61,63",
"    </a>",
"    ]. A similar syndrome has been observed in TPO-transfected mice [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/62,65\">",
"     62,65",
"    </a>",
"    ] and has been attributed to increased TGF-beta activity secondary to an increased megakaryocyte mass [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Although the process was reversible by bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/62\">",
"     62",
"    </a>",
"    ], chronic exposure led to a fatal myeloproliferative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of TPO has been further evaluated in immune-compromised mice. Overexpression of the TPO gene using adenovectors in SCID mice (severe combined immune deficient) resulted in thrombocytosis, increased marrow megakaryocytes, fibrosis, and extramedullary hematopoiesis that mimicked PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/66\">",
"     66",
"    </a>",
"    ]. However, similar overexpression of thrombopoietin in NOD-SCID mice (which have reduced monocyte and macrophage function in addition to the lymphocyte deficiency in SCID mice) produced thrombocytosis and megakaryocytosis but no fibrosis. These results imply that other",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    mediators are involved in causing the fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above discussion supports the pathogenetic role of TGF-beta in BMF. The pathogenetic interaction of TPO and TGF-beta in the human disease has not been elucidated. Serum TPO concentrations in patients with PMF are higher than those of normal volunteers or patients with reactive thrombocytosis and have been correlated with the degree of BMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. However, there was no correlation with megakaryocyte mass, and the demonstration of low TPO-receptor (c-Mpl) expression by platelets and megakaryocytes from patients with PMF suggests that defective TPO clearance may contribute to the above normal TPO values in patients with PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, CD34+ hematopoietic progenitor cells from patients with PMF have increased expression of mRNA transcripts of bFGF and its receptors and decreased expression of TGF-beta type II receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/71\">",
"     71",
"    </a>",
"    ]. The pathogenetic and clinical relevance of these observations is currently unknown, although the myeloproliferation characteristic of this disease may result from abnormal proliferation of these precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EXTRAMEDULLARY HEMATOPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms responsible for extramedullary hematopoiesis (EMH) in PMF are not understood. The distribution of hematopoietic tissue approximates that in the fetus. In both a mouse model of marrow fibrosis and in marrow fibrosis associated with metastatic disease, there is abnormal release of marrow precursors into distorted bone marrow sinusoids and then into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. These marrow precursors may be responsible for EMH in PMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/74,75\">",
"     74,75",
"    </a>",
"    ], although increased trafficking of CD34+ cells into the circulation may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\", section on 'Circulating CD34+ cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Foci of EMH may also be found in soft tissues, body cavities, serosal surfaces, central nervous system, skin, and other locations. EMH may resemble tumors at these sites, often causing obstructive symptoms, especially in the central nervous system. Such foci may enlarge significantly postsplenectomy, perhaps due to the loss of filtering function of the spleen.",
"   </p>",
"   <p>",
"    In some patients with PMF, hematopoiesis is only present in extramedullary sites [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/77\">",
"     77",
"    </a>",
"    ]. EMH is rarely as effective as medullary hematopoiesis, thereby leading to the cytopenias so often found in this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INCREASED BONE MARROW VASCULARITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have shown that bone marrow microvessel density (MVD) is increased in patients with PMF and other",
"    <span class=\"nowrap\">",
"     BCR/ABL1-negative",
"    </span>",
"    myeloproliferative neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. In one of the studies, MVD was significantly increased in 114 patients with PMF, when compared with bone marrows from 44 normal controls, 15 patients with polycythemia vera and 17 with essential thrombocythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/78\">",
"     78",
"    </a>",
"    ]. This phenomenon, as with bone marrow fibrosis, is thought to be secondary to release of several growth factors by megakaryocytes (eg, VEGF, PDGF, TGF-beta, bFGF). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Bone marrow fibrosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In this study, increased MVD significantly correlated with the presence of megakaryocyte clumping, increased splenic size, and, in a multivariate model, decreased overall survival. Based on these correlations, phase II studies employing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , agents with antiangiogenic properties, are ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25064/abstract/5,78,81\">",
"     5,78,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link&amp;anchor=H22#H22\">",
"     \"Prognosis and treatment of primary myelofibrosis\", section on 'Thalidomide and lenalidomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H117146124#H117146124\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Imunomodulatory drugs (IMiDs)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15533413\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary myelofibrosis (PMF, chronic idiopathic myelofibrosis) is characterized by chronic myeloproliferation, atypical megakaryocytic hyperplasia, increased bone marrow vascularity, and bone marrow fibrosis (BMF), the latter two features likely resulting from proliferation and hyperactivity of non-clonal fibroblasts induced by growth factors shed from clonally expanded megakaryocytes. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Bone marrow fibrosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Increased bone marrow vascularity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    BMF contributes to the impaired hematopoiesis, severe anemia, marked splenomegaly, extramedullary hematopoiesis, and severe constitutional symptoms characteristic of PMF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Extramedullary hematopoiesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following features have been implicated in the pathogenesis of PMF and BMF (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Overview'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chromosomal abnormalities (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Chromosomal and other genetic abnormalities'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Abnormal megakaryocyte growth (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Spontaneous hematopoietic colony growth in vitro'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Abnormalities of the",
"      <span class=\"nowrap\">",
"       JAK/STAT",
"      </span>",
"      pathway and MPL mutations (see",
"      <a class=\"local\" href=\"#H6\">",
"       'JAK/STAT pathway'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'MPL mutations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Excessive cytokines (see",
"      <a class=\"local\" href=\"#H12005307\">",
"       'Cytokine abnormalities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Transforming growth factor-beta'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Overexpression of thrombopoietin (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Thrombopoietin'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/1\">",
"      Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31:737.",
"     </a>",
"    </li>",
"    <li>",
"     Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofibrosis. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL (Eds) (Eds), IARC Press, Lyon 2008. p.44.",
"    </li>",
"    <li>",
"     Thiele J, Pierre R, Imbert M, et al. Chronic idiopathic myelofibrosis. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/4\">",
"      Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007; 110:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/5\">",
"      Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23:8520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/6\">",
"      Smith RE, Chelmowski MK, Szabo EJ. Myelofibrosis: a review of clinical and pathologic features and treatment. Crit Rev Oncol Hematol 1990; 10:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/7\">",
"      Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/8\">",
"      Lataillade JJ, Pierre-Louis O, Hasselbalch HC, et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 2008; 112:3026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/9\">",
"      Bosch X, Campistol JM, Montoliu J, et al. Toluene-associated myelofibrosis. Blut 1989; 58:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/10\">",
"      Bosch X, Campistol JM, Montoliu J, Revert L. Myelofibrosis and focal segmental glomerulosclerosis associated with toluene poisoning. Hum Toxicol 1988; 7:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/11\">",
"      Visfeldt J, Andersson M. Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide. APMIS 1995; 103:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/12\">",
"      ANDERSON RE, HOSHINO T, YAMAMOTO T. MYELOFIBROSIS WITH MYELOID METAPLASIA IN SURVIVORS OF THE ATOMIC BOMB IN HIROSHIMA. Ann Intern Med 1964; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/13\">",
"      Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood 2002; 100:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/14\">",
"      Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 2005; 105:3493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/15\">",
"      Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/16\">",
"      Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997; 98:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/17\">",
"      Sinclair EJ, Forrest EC, Reilly JT, et al. Fluorescence in situ hybridization analysis of 25 cases of idiopathic myelofibrosis and two cases of secondary myelofibrosis: monoallelic loss of RB1, D13S319 and D13S25 loci associated with cytogenetic deletion and translocation involving 13q14. Br J Haematol 2001; 113:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/18\">",
"      Tefferi A, Mesa RA, Schroeder G, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 113:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/19\">",
"      Tefferi A, Dingli D, Li CY, Dewald GW. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer 2005; 104:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/20\">",
"      Strasser-Weippl K, Steurer M, Kees M, et al. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia. Cancer 2006; 107:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/21\">",
"      Demory JL, Dupriez B, Fenaux P, et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 1988; 72:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/22\">",
"      Tefferi A, Pardanani A, Gangat N, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia 2012; 26:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/23\">",
"      Al-Assar O, Ul-Hassan A, Brown R, et al. Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study. Br J Haematol 2005; 129:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/24\">",
"      Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010; 115:2882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/25\">",
"      Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012; 26:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/26\">",
"      Beer PA, Delhommeau F, LeCou&eacute;dic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010; 115:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/27\">",
"      Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012; 119:4480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/28\">",
"      Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012; 120:4168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/29\">",
"      Poletto V, Rosti V, Villani L, et al. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood 2012; 120:3112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/30\">",
"      Wang JC, Lang HD, Lichter S, et al. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 1992; 80:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/31\">",
"      Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood 2003; 101:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/32\">",
"      Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/33\">",
"      Taksin AL, Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 1999; 93:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/34\">",
"      Li Y, Hetet G, Kiladjian JJ, et al. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Br J Haematol 1996; 92:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/35\">",
"      Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3:e270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/36\">",
"      Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108:3472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/37\">",
"      Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/38\">",
"      Castro-Malaspina H, Jhanwar SC. Properties of myelofibrosis-derived fibroblasts. Prog Clin Biol Res 1984; 154:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/39\">",
"      Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/40\">",
"      Lisse I, Hasselbalch H, Junker P. Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases. An immunohistochemical study. APMIS 1991; 99:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/41\">",
"      Groopman JE. The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med 1980; 92:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/42\">",
"      Castro-Malaspina H, Rabellino EM, Yen A, et al. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 1981; 57:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/43\">",
"      Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007; 139:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/44\">",
"      Kimura A, Katoh O, Kuramoto A. Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-beta on the growth of human marrow fibroblasts. Br J Haematol 1988; 69:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/45\">",
"      Martyr&eacute; MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997; 97:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/46\">",
"      Dalley A, Smith JM, Reilly JT, Neil SM. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol 1996; 93:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/47\">",
"      Bock O, Muth M, Theophile K, et al. Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis. Br J Haematol 2009; 146:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/48\">",
"      Papadantonakis N, Matsuura S, Ravid K. Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection. Blood 2012; 120:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/49\">",
"      Murate T, Yamashita K, Isogai C, et al. The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br J Haematol 1997; 99:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/50\">",
"      Wang JC, Novetsky A, Chen C, Novetsky AD. Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis. Br J Haematol 2002; 119:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/51\">",
"      Schmitt A, Jouault H, Guichard J, et al. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000; 96:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/52\">",
"      Terui T, Niitsu Y, Mahara K, et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 1990; 75:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/53\">",
"      Ignotz RA, Massagu&eacute; J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261:4337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/54\">",
"      Kimura A, Katoh O, Hyodo H, Kuramoto A. Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 1989; 72:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/55\">",
"      Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997; 11:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/56\">",
"      Martyr&eacute; MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994; 88:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/57\">",
"      K&auml;h&auml;ri VM, Chen YQ, Su MW, et al. Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1. Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels. J Clin Invest 1990; 86:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/58\">",
"      Chang VT, Yook C, Rameshwar P. Synergism between fibronectin and transforming growth factor-&beta;1 in the production of substance P in monocytes of patients with myelofibrosis. Leuk Lymphoma 2013; 54:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/59\">",
"      Rameshwar P, Chang VT, Thacker UF, Gasc&oacute;n P. Systemic transforming growth factor-beta in patients with bone marrow fibrosis--pathophysiological implications. Am J Hematol 1998; 59:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/60\">",
"      Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997; 90:4369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/61\">",
"      Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996; 87:5006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/62\">",
"      Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996; 88:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/63\">",
"      Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997; 99:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/64\">",
"      Abina MA, Tulliez M, Lacout C, et al. Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: risk of sustained expression inducing myelofibrosis due to immunosuppression. Gene Ther 1998; 5:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/65\">",
"      Yan XQ, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 1995; 86:4025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/66\">",
"      Frey BM, Rafii S, Teterson M, et al. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 1998; 160:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/67\">",
"      Wang JC, Chen C, Lou LH, Mora M. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia 1997; 11:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/68\">",
"      Wang JC, Chen C, Novetsky AD, et al. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis. Am J Med 1998; 104:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/69\">",
"      Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998; 338:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/70\">",
"      Sasaki A, Katoh O, Kawaishi K, et al. Expression of c-Mpl and c-Mpl ligand gene in hematopoietic cells of individuals with and without myeloproliferative disorders and leukemia cell lines. Int J Hematol 1995; 62:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/71\">",
"      Le Bousse-Kerdil&egrave;s MC, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996; 88:4534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/72\">",
"      Xu M, Bruno E, Chao J, et al. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 2005; 105:1699.",
"     </a>",
"    </li>",
"    <li>",
"     Silverstein MN. Agnogenic myeloid metaplasia, Publishing Sciences Group, Acton, MA 1975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/74\">",
"      O'Keane JC, Wolf BC, Neiman RS. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 1989; 63:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/75\">",
"      Wolf BC, Neiman RS. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 1985; 65:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/76\">",
"      Xu M, Bruno E, Chao J, et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 2005; 105:4508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/77\">",
"      Ferrant A, Rodhain J, Cauwe F, et al. Assessment of bone marrow and splenic erythropoiesis in myelofibrosis. Scand J Haematol 1982; 29:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/78\">",
"      Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96:3374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/79\">",
"      Boveri E, Passamonti F, Rumi E, et al. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol 2008; 140:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/80\">",
"      Medinger M, Skoda R, Gratwohl A, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol 2009; 146:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25064/abstract/81\">",
"      Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006; 106:1974.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4526 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25064=[""].join("\n");
var outline_f24_30_25064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15533413\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CELLULAR ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chromosomal and other genetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12005307\">",
"      Cytokine abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Spontaneous hematopoietic colony growth in vitro",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      JAK/STAT pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - JAK2 mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - MPL mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BONE MARROW FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transforming growth factor-beta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EXTRAMEDULLARY HEMATOPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INCREASED BONE MARROW VASCULARITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15533413\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4526\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4526|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/16/24835\" title=\"figure 1\">",
"      Organiz heme malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/44/20162\" title=\"figure 2\">",
"      Pathogenesis of AMM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4526|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/32/13835\" title=\"table 1\">",
"      Cytogenetic abnormalities AMM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=related_link\">",
"      Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=related_link\">",
"      Prognosis and treatment of primary myelofibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_30_25065="Amiodarone and thyroid dysfunction";
var content_f24_30_25065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amiodarone and thyroid dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25065/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25065/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25065/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/30/25065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    , a class III anti-arrhythmic drug, has multiple effects on myocardial depolarization and repolarization that make it an extremely effective antiarrhythmic drug. However, amiodarone is associated with a number of side effects, including thyroid dysfunction (both hypo- and hyperthyroidism), which is due to amiodarone's high iodine content and its direct toxic effect on the thyroid. This topic will review the major effects of amiodarone on thyroid function. The clinical use and other side effects of amiodarone are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    contains two iodine atoms. It is estimated that amiodarone metabolism in the liver releases approximately 3 mg of inorganic iodine into the systemic circulation per 100 mg of amiodarone ingested. The average iodine content in a typical American diet is about 0.3",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Thus, 6 mg of iodine associated with a 200 mg dose of amiodarone markedly increases the daily iodine load [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is very lipophilic and is concentrated in adipose tissue, cardiac and skeletal muscle, and the thyroid. Elimination from the body occurs with a half-life of about 100 days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/3\">",
"     3",
"    </a>",
"    ]. Amiodarone toxicity can therefore occur well after drug withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    on thyroid function can be divided into those effects that are intrinsic properties of the drug, and those effects that are due to iodine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Intrinsic drug effects",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      inhibits outer ring 5'-monodeiodination of T4, thus decreasing T3 production; reverse T3 accumulates since it is not metabolized to T2 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      , and particularly the metabolite desethylamiodarone, blocks T3-receptor binding to nuclear receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/6\">",
"       6",
"      </a>",
"      ] and decreases expression of some thyroid hormone-related genes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      may have a direct toxic effect on thyroid follicular cells, which results in a destructive thyroiditis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Type II'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effects due to iodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine is a substrate for thyroid hormone synthesis. It is actively transported into thyroid follicular cells and organified onto tyrosyl residues in thyroglobulin.",
"   </p>",
"   <p>",
"    The normal autoregulation of iodine prevents normal individuals from becoming hyperthyroid after exposure to an iodine load (eg, radiocontrast). When intrathyroidal iodine concentrations reach a critical high level, iodine transport and thyroid hormone synthesis are transiently inhibited until intrathyroidal iodine stores return to normal levels (the Wolff-Chaikoff effect). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with underlying thyroid disease, however, have defects in autoregulation of iodine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with autoimmune thyroid disease \"fail to escape\" from the Wolff-Chaikoff effect. The result is the development of goiter and hypothyroidism in Hashimoto's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/9\">",
"       9",
"      </a>",
"      ] and amelioration of Graves' hyperthyroidism.",
"     </li>",
"     <li>",
"      Patients with areas of autonomous function within a nodular goiter do not autoregulate iodine and the addition of more substrate may result in excessive thyroid hormone synthesis and thyrotoxicosis (Jod-Basedow) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK OF THYROID DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both hypo- and hyperthyroidism are complications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/1,11-14\">",
"     1,11-14",
"    </a>",
"    ]. In a meta-analysis of four randomized trials involving 1465 euthyroid patients, the prevalence of clinical thyroid disease was higher in patients receiving amiodarone therapy (150 to 330",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for a minimum of one year) when compared with placebo (3.7 versus 0.4 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/13\">",
"     13",
"    </a>",
"    ]. In other reviews and reports, the risk of amiodarone-induced thyroid dysfunction ranges from 2 to 30 percent, depending upon an individual's underlying thyroid status, dietary iodine intake, and whether cases of subclinical thyroid disorders (eg, slight rise in TSH without symptoms) are included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/1,11,12,14-16\">",
"     1,11,12,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Underlying thyroid function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    on thyroid function in any individual are dependent upon the underlying status of that individual's thyroid gland.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Normal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal, euthyroid individuals receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , acute changes in thyroid function tests include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum T4 and free T4 concentrations rise by 20 to 40 percent during the first month of therapy.",
"     </li>",
"     <li>",
"      Serum T3 concentrations decrease by up to 30 percent within the first few weeks of therapy.",
"     </li>",
"     <li>",
"      Serum reverse T3 concentrations increase by 20 percent soon after the initiation of therapy.",
"     </li>",
"     <li>",
"      The serum TSH concentration usually rises slightly after the initiation of treatment and may exceed the upper limit of normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After three to six months of therapy, a steady state is reached in most patients who were euthyroid at baseline:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum TSH concentration normalizes.",
"     </li>",
"     <li>",
"      Serum total T4, free T4 and rT3 concentrations remain slightly elevated or in the upper normal range.",
"     </li>",
"     <li>",
"      Serum T3 concentrations remain in the low normal range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    may also cause a destructive thyroiditis in patients without underlying thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Type II'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Abnormal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with underlying autoimmune thyroid disease are more likely to develop",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      -induced hypothyroidism, presumably due to failure to escape from the Wolff-Chaikoff effect. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effects due to iodine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Hypothyroidism'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients with underlying multinodular goiter or latent Graves' disease, hyperthyroidism (increased synthesis of T4 and T3) may occur. The excess iodine from the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      provides increased substrate, resulting in enhanced thyroid hormone production [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Type I'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dietary iodine intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary iodine intake also affects an individual's risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced thyroid dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In iodine-sufficient areas,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      -induced hypothyroidism appears to be more common than hyperthyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/15,18-20\">",
"       15,18-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      -induced hyperthyroidism is more common than hypothyroidism in iodine-deficient regions [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study illustrates the importance of both the underlying thyroid status and dietary iodine intake in relation to the risk of developing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced thyroid dysfunction. In Worcester, Massachusetts, an area with iodine sufficiency and a high prevalence of autoimmune thyroid disease, amiodarone was associated with a 22 percent rate of hypothyroidism and a 2 percent rate of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, in Pisa, Italy, an area of borderline iodine intake and a high prevalence of nodular goiter, amiodarone was associated with a 5 percent rate of hypothyroidism and a 9.6 percent rate of hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HYPOTHYROIDISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, transient changes in thyroid function tests often occur in euthyroid individuals treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . However, most patients remain euthyroid during amiodarone therapy (89 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/21\">",
"     21",
"    </a>",
"    ]. In one trial, overt hypothyroidism (TSH &gt;10",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    developed in 5 percent of patients receiving amiodarone, but subclinical hypothyroidism (TSH 4.5 to 10",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    developed in an additional 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with underlying Hashimoto's thyroiditis or positive antithyroid antibodies are more likely to develop persistent hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. This observation may explain the higher prevalence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced hypothyroidism in women compared to men [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In iodine-sufficient areas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced hypothyroidism is more common than hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/15,18-20\">",
"     15,18-20",
"    </a>",
"    ], and may occur in up to 20 percent of patients treated with amiodarone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, amiodarone-induced hyperthyroidism is more common than hypothyroidism in iodine-deficient regions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Dietary iodine intake'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient hypothyroidism may occur in the infants of women treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    during pregnancy. As an example, in a study of 64 pregnancies in which amiodarone was given to the mother, 11 infants (17 percent) had transient hypothyroidism; 2 of the 11 had a goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/23\">",
"     23",
"    </a>",
"    ]. Hypothyroidism was transient in all cases and only five infants were treated short-term with thyroid hormones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations and diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -associated hypothyroidism are similar to those of hypothyroidism from any cause. Hypothyroidism and hypothyroid symptoms may develop as soon as two weeks or as late as 39 months after the initiation of amiodarone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should have thyroid function assessed several weeks after starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and every few months thereafter for the development of overt hypothyroidism, especially those with evidence for autoimmunity prior to initiating amiodarone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. Hypothyroidism should be diagnosed on the basis of a screening serum TSH value before the patient has symptoms. Since small increases in serum TSH concentrations (10 to 20",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    are seen in euthyroid patients for the first three to six months after amiodarone therapy is initiated, amiodarone-induced hypothyroidism should only be diagnosed when serum T4 concentrations are low-normal or low, or mild TSH elevation persists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function can be easily normalized by replacement with T4 while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is continued. The goal of therapy is to restore the serum TSH concentration to normal, keeping in mind that a larger than usual dose may be required because of the likely effects of amiodarone on intrapituitary T4 metabolism and T3 production, and possibly thyroid hormone action [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/11\">",
"     11",
"    </a>",
"    ]. The patient should be retested if amiodarone is withdrawn at a later date. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is usually",
"    <strong>",
"     not",
"    </strong>",
"    discontinued unless it fails to control the underlying arrhythmia. However, if amiodarone is stopped, hypothyroidism in patients with no apparent preexisting thyroid disease often resolves. In contrast, hypothyroidism may persist after withdrawal of amiodarone in patients who have underlying chronic autoimmune thyroiditis with high titers of anti-TPO antibodies and goiter, and they therefore require permanent T4 therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/1,4,11,12,22\">",
"     1,4,11,12,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HYPERTHYROIDISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Types of hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced thyrotoxicosis (AIT). In type 1, there is increased synthesis of thyroid hormone, whereas in type 2 there is excess release of T4 and T3 due to a destructive thyroiditis. These types differ in their pathogenesis, management, and outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;In type I AIT, there is hyperthyroidism with increased synthesis of T4 and T3. This type is typically seen in patients with pre-existing multinodular goiter or latent Graves' disease; the excess iodine from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    provides increased substrate, resulting in enhanced thyroid hormone production [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/17\">",
"     17",
"    </a>",
"    ]. While most of these patients have underlying multinodular goiter, occasional patients have latent Graves' disease that becomes overt upon exposure to large amounts of iodine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;In type II AIT, the hyperthyroidism is a destructive thyroiditis that results in excess release of T4 and T3, without increased hormone synthesis. It typically occurs in patients without underlying thyroid disease, and is caused by a direct toxic effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    on thyroid follicular epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hyperthyroid phase may last from several weeks to several months, and it is often followed by a hypothyroid phase with eventual recovery in most, but not all patients. For unclear reasons, the toxic effects of the drug may take two to three years to become manifest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link\">",
"     \"Overview of thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many cases, mixed forms of AIT exist, making both diagnosis and treatment challenging. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment'",
"    </a>",
"    above.) The risk of either type increases with higher cumulative doses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of AIT, as well as the distribution by type (I or II), varies by geographical region. This is thought to be primarily due to differences in dietary iodine intake (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Dietary iodine intake'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, 3 to 5 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      become hyperthyroid, usually between four months and three years after the initiation of the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/14,22\">",
"       14,22",
"      </a>",
"      ]. The majority of cases are type II.",
"     </li>",
"     <li>",
"      In iodine-deficient regions, AIT is more common than in the United States, occurring in approximately 10 to 12 percent of patients with type I AIT usually predominating [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/11,12,15\">",
"       11,12,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the distribution of cases by type may be changing, as illustrated in a report of 215 consecutive patients with AIT seen at a single institution in Italy over 26 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/31\">",
"     31",
"    </a>",
"    ]. In 1980 compared to 2006, two of six (40 percent) versus 12 of 14 (86 percent) of new AIT cases were type II. Possible explanations for this observation include improved dietary iodine intake in the region, and the avoidance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in patients with known thyroid disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced hyperthyroidism are often masked because its beta-blocking activity minimizes many of the adrenergic manifestations of thyroid hormone excess, and possibly because amiodarone metabolites may block binding of T3 to its nuclear receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common presenting symptoms and signs include the development or redevelopment of atrial arrhythmias, exacerbation of ischemic heart disease or heart failure, or unexplained weight loss, restlessness, or low-grade fever [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced hyperthyroidism have a threefold higher rate of major adverse cardiovascular events (mostly ventricular arrhythmias) compared to euthyroid controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/32\">",
"     32",
"    </a>",
"    ]. The presence of severe left ventricular dysfunction in patients with amiodarone-induced hyperthyroidism (type I or type II) may be associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Differentiating the two types",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between type I and type II is critical, since therapy differs for the two types. However, the distinction may be difficult using clinical criteria, partly because some patients may have a mixture of both mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/29\">",
"     29",
"    </a>",
"    ]. Thyroid function tests are not helpful for differentiating type I from type II hyperthyroidism.",
"   </p>",
"   <p>",
"    In patients not taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , the radioiodine uptake is the primary test used to distinguish between destructive subacute thyroiditis and hyperthyroidism associated with de novo synthesis of thyroid hormone: the 24-hour radioiodine uptake is &lt;1 percent in subacute thyroiditis, and elevated or normal in toxic nodular goiter or Graves' disease.",
"   </p>",
"   <p>",
"    However, the daily ingestion of 6 g or more of bioavailable iodine with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    results in sufficiently high serum levels of iodine that compete with the tracer used to perform the uptake test. Therefore, the majority of patients with type I (as well as all patients with type II) has uptakes that are less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/34\">",
"     34",
"    </a>",
"    ]. In one European study, a significant percentage of patients with type I hyperthyroidism had measurable or even elevated uptakes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/35\">",
"     35",
"    </a>",
"    ]; however, this is an unusual finding in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The criteria used to attempt to distinguish type I from type II hyperthyroidism are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the 24-hour radioiodine uptake is detectable, it suggests type I AIT [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with type I often have multinodular goiters or diffuse goiter, whereas those with type II usually have no goiter or a small diffuse goiter.",
"     </li>",
"     <li>",
"      In two studies, serum thyroglobulin concentrations were higher and serum interleukin-6 concentrations were lower in patients with type I hyperthyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/25,28\">",
"       25,28",
"      </a>",
"      ]. In a third study, interleukin-6 concentrations were not useful for distinguishing type I from type II [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two studies reported that color flow Doppler sonography (CFDS) may distinguish type I (increased vascularity) from type II (absent vascularity) hyperthyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]; 80 percent of patients could be classified by CFDS.",
"      <br/>",
"      <br/>",
"      However, interpretations of CFDS in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      -associated hyperthyroidism require an experienced sonographer. It is straightforward to separate patients into those with increased and low flow when a group of patients with amiodarone-associated hyperthyroidism are being scanned sequentially, but due to the lack of an accepted \"gold standard,\" it may be difficult to interpret the CFDS of a single thyroid gland scanned during a typical day of multi-organ ultrasound examinations.",
"     </li>",
"     <li>",
"      A preliminary report utilized 99mTc-sestaMIBI thyroid uptake and scintigraphy to distinguish type I (normal or increased) from type II (decreased) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/38\">",
"       38",
"      </a>",
"      ]. If confirmed, this may prove more useful than CFDS.",
"     </li>",
"     <li>",
"      The presence of thyrotropin receptor antibodies suggests Graves' disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Should amiodarone be discontinued?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data that directly address this question. In a retrospective study from Italy of type 2 AIT, the median time to normalize thyroid function was similar whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    was continued (n = 8) or discontinued (n = 32) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/39\">",
"     39",
"    </a>",
"    ]. However, five of seven patients taking amiodarone had recurrent thyrotoxicosis compared with 3 of 32 patients in whom the amiodarone was discontinued. In a study from the Netherlands of type 2 AIT in which 36 patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , sodium perchlorate, or both, therapy was effective in all patients receiving prednisone or perchlorate plus prednisone, despite continuation of amiodarone in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/40\">",
"     40",
"    </a>",
"    ]. Recurrent thyrotoxicosis occurred in only three patients (8 percent).",
"   </p>",
"   <p>",
"    When deciding whether to discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , the following should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      may be necessary to control a life-threatening arrhythmia.",
"     </li>",
"     <li>",
"      Since the half-life of elimination from the body is about 100 days, there is no immediate benefit to stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      appears to ameliorate hyperthyroidism by blocking T4 to T3 conversion, beta-adrenergic receptors, and possibly T3 receptors. Stopping amiodarone might actually exacerbate hyperthyroid symptoms and signs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who develop AIT in whom the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    was prescribed for life-threatening ventricular arrhythmias (and is effective), we suggest continuing the amiodarone and simultaneously treating the hyperthyroidism. If the amiodarone was not prescribed for life-threatening ventricular arrhythmias (or is ineffective), we suggest discontinuing the drug in consultation with the patient&rsquo;s cardiologist if alternative antiarrhythmics can be used. For type I AIT, amiodarone should not be discontinued until hyperthyroid symptoms are well controlled with thionamides, since worsening hyperthyroid symptoms due to increased T3 levels may occur when the amiodarone is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H756510\">",
"    <span class=\"h3\">",
"     Treatment of type I AIT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     Thionamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type I hyperthyroidism usually respond to a thionamide drug, although the response may be slow and large doses may be required, presumably because of very high intrathyroidal iodine stores [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/4,42\">",
"     4,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Higher than average doses are often needed, eg, 30 to 40 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    daily, with careful monitoring for adverse effects such as skin rash, arthralgia, hepatotoxicity and, rarely, bone marrow suppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link&amp;anchor=H5#H5\">",
"     \"Pharmacology and toxicity of thionamides\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of perchlorate, which blocks further iodine uptake by the thyroid, may be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/43\">",
"     43",
"    </a>",
"    ], but chronic use has been associated (rarely) with aplastic anemia, and perchlorate is not currently available in the United States. The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    carbonate to the antithyroid drug has also been reported to speed recovery when the hyperthyroidism is severe [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thionamides are usually tapered to a low maintenance dose in patients with hyperthyroidism. In",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -associated type I hyperthyroidism, care must be taken not to reduce the dose of thionamide too quickly or patients might develop recurrent and prolonged hyperthyroidism. An alternative strategy is to continue high dose thionamides and add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    after patients become hypothyroid.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is stopped (eg, if there is evidence of toxicity in other organs or if it is ineffective as an anti-arrhythmic), depending upon the clinical setting one might add beta-adrenergic blocking drugs and iopanoic acid to block T4 to T3 conversion. However, neither iopanoic acid nor ipodate are available in the United States. It is unclear when, or even whether, they will ever again be marketed in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=see_link\">",
"     \"Iodinated radiocontrast agents in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with iodine-induced hyperthyroidism who are continuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    will need to continue thionamides. If amiodarone is subsequently discontinued, the thionamide should be continued until measurement of urine iodine returns to normal. This may take 6 to 18 months, after which one could cautiously attempt to taper antithyroid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h4\">",
"     Radioiodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the radioiodine uptake is high enough, one could treat the patient with radioiodine. In one series of 14 patients in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    had been discontinued due to hyperthyroidism, subsequent radioiodine ablation of the thyroid allowed reintroduction of amiodarone (and control of recurrent tachyarrhythmias) in 12 of the 14 subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/45\">",
"     45",
"    </a>",
"    ]. However, radioiodine ablation is usually not an option due to low radioiodine uptake in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h4\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are refractory to antithyroid drug therapy should be treated by thyroidectomy. When balancing the risk of a surgical procedure during careful cardiovascular monitoring with the risk of several months of unmonitored and uncontrolled thyrotoxicosis, the advantages of surgery in this setting become compelling [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link\">",
"     \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Treatment of type II AIT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h4\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type II hyperthyroidism respond well to moderately large doses of corticosteroids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 to 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/25,49\">",
"     25,49",
"    </a>",
"    ], even if the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is continued [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/34,50\">",
"     34,50",
"    </a>",
"    ]. We typically start with prednisone (40 to 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and continue therapy for one to three months before tapering (to avoid exacerbations of hyperthyroidism). Some improvement is usually seen as early as one week [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/25\">",
"     25",
"    </a>",
"    ]. In one study of 66 patients, 60 percent were euthyroid within one month and 16 percent remained hyperthyroid for more than three months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/51\">",
"     51",
"    </a>",
"    ]. Prolonged hyperthyroidism was associated with higher serum free T4 levels and goiter.",
"   </p>",
"   <p>",
"    Glucocorticoid therapy is more effective than iopanoic acid. In a prospective, randomized trial, both glucocorticoids and iopanoic acid were effective in type II hyperthyroidism, but thyroid function returned to normal more rapidly after steroid administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=see_link\">",
"     \"Iodinated radiocontrast agents in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized clinical trial, the addition of perchlorate to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    added no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with type II AIT may develop transient (or sometimes permanent) hypothyroidism when the hyperthyroidism resolves [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/8\">",
"     8",
"    </a>",
"    ] and benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link\">",
"     \"Overview of thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Treatment if mechanism unknown",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients may have a \"mixed\" form of thyrotoxicosis or the underlying cause (type I or type II) may be uncertain. In such cases, a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is prudent initial therapy. A rapid response suggests type II hyperthyroidism; the methimazole can then be tapered or stopped and, if indicated, iopanoic acid can be added (if available). A poor response initially argues for type I hyperthyroidism. If so, steroids can be tapered and, depending upon the subsequent course, perchlorate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since thyroid dysfunction is relatively common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy, all patients should have thyroid function tests checked before starting therapy and at three to four month intervals during treatment and for at least one year after the drug is withdrawn [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PATIENTS ON WARFARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    who are also being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the consequences of amiodarone-induced thyroid dysfunction include a significant influence on warfarin response. The effect of warfarin is potentiated by thyrotoxicosis and attenuated in hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25065/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, amiodarone itself has effects on warfarin pharmacokinetics, which may be important if the amiodarone is discontinued because of thyroid dysfunction. In any patient with amiodarone-induced thyroid dysfunction who is also taking warfarin, the International Normalized Ratio (INR) should be monitored closely and appropriate adjustments in warfarin dosing made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid dysfunction (both hypo- and hyperthyroidism) is a common complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy due to direct effects of the drug on the thyroid, as well as its high iodine content:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      on the thyroid include: inhibition of outer ring 5'-monodeiodination of T4, thus decreasing T3 production; blocking T3-receptor binding to nuclear receptors; decreased expression of some thyroid hormone-related genes; and a direct toxic effect on the thyroid (destructive thyroiditis). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Intrinsic drug effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other effects on the thyroid are due to the extremely high iodine content of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effects due to iodine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Predictors of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;An individual's risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced hypo- or hyperthyroidism is dependent upon underlying thyroid status and dietary iodine intake:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with underlying autoimmune thyroid disease are at highest risk for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      -induced hypothyroidism (due to failure to escape from the Wolff-Chaikoff effect). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Abnormal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with nodular goiter are at increased risk of type 1 AIT. The excess iodine from the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      provides increased substrate, resulting in enhanced thyroid hormone synthesis and hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Type I'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Destructive thyroiditis (type II AIT) typically occurs in patients with no underlying thyroid disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Type II'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dietary iodine intake also affects an individual's risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      -induced thyroid dysfunction. In iodine-sufficient areas, amiodarone-induced hypothyroidism appears to be more common than hyperthyroidism. In contrast, amiodarone-induced hyperthyroidism (usually type I AIT) is more common than hypothyroidism in iodine-deficient regions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced hypothyroidism is essentially the same as for any patient with hypothyroidism, although higher doses of thyroxine may be required to normalize the serum TSH level. The mainstays of therapy for amiodarone-induced hyperthyroidism are thionamides and glucocorticoids for type I and type II AIT, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient changes in thyroid function tests often occur in euthyroid individuals treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . While most patients remain euthyroid during amiodarone therapy, patients with pre-existing autoimmune thyroid disease (subclinical Hashimoto's thyroiditis or positive antithyroid antibodies) are at increased risk of developing amiodarone-induced hypothyroidism. The diagnosis and treatment of these patients is the same as for other patients with primary hypothyroidism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest continuing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      therapy in patients who develop amiodarone-induced hypothyroidism (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Euthyroidism should be restored by replacement with thyroid hormone. Thyroid hormone, in doses larger than normal, is often required. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      should only be discontinued if it fails to control the underlying arrhythmia. If amiodarone is discontinued in a patient without pre-existing autoimmune thyroid disease, the hypothyroidism often resolves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243059672\">",
"    <span class=\"h3\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced thyrotoxicosis (AIT). In type 1, there is increased synthesis of thyroid hormone, whereas in type 2 there is excess release of T4 and T3 due to a destructive thyroiditis. However, it is often difficult to distinguish between the two types and some patients may have elements of both. The 24-hour radioiodine uptake is typically",
"    <strong>",
"     not",
"    </strong>",
"    able to distinguish between types I and II AIT because the high levels of ingested iodine with amiodarone results in 24-hour uptakes of less than 1 percent in most patients with either type I or type II AIT. Color flow Doppler sonography may be the best way of distinguishing between the two types of AIT. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Differentiating the two types'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who develop AIT in whom the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      was prescribed for life-threatening ventricular arrhythmias (and is effective), we suggest continuing the amiodarone and simultaneously treating the hyperthyroidism (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Should amiodarone be discontinued?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      was not prescribed for life-threatening ventricular arrhythmias (or is ineffective), we suggest discontinuing the drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This should only be done in consultation with the patient&rsquo;s cardiologist if alternative antiarrhythmics can be used. For type I AIT, amiodarone should not be discontinued until hyperthyroid symptoms are well controlled with thionamides, since worsening hyperthyroid symptoms due to increased T3 levels may occur when the amiodarone is discontinued. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Should amiodarone be discontinued?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h4\">",
"     Type I AIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I AIT is hyperthyroidism with increased synthesis of T4 and T3; the excess iodine provides increased substrate, resulting in enhanced thyroid hormone production.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest thionamides as our first choice of therapy to treat type I AIT (whether",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is continued or discontinued) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Thionamides'",
"      </a>",
"      above.) Although radioiodine ablation has been reported to have been used (in rare patients with high enough radioiodine uptake), this is usually not an option due to low radioiodine uptake in the majority of type I patients. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Radioiodine'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Higher than average doses of thionamides are usually needed (30 to 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      or 450 to 600 mg PTU daily). Perchlorate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      are sometimes added to speed recovery, however, perchlorate is not available in the US. In addition, perchlorate has been associated, albeit rarely, with aplastic anemia. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Thionamides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients are refractory to antithyroid drug therapy; they should be treated by thyroidectomy. When balancing the risk of a surgical procedure during careful cardiovascular monitoring with the risk of several months of unmonitored and uncontrolled thyrotoxicosis, the advantages of surgery in this setting become compelling. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h4\">",
"     Type II AIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II AIT is a destructive thyroiditis that results in the release of excess T4 and T3, but not increased synthesis. It is typically seen in patients without underlying thyroid disease, and is caused by a direct toxic effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    on the thyroid gland. The hyperthyroid phase may last from several weeks to several months, and is often followed by a hypothyroid phase and then recovery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who develop type II AIT, we suggest glucocorticoid therapy as our first-line drug (whether",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is continued or discontinued) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We typically start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (40 to 60",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      and continue therapy for one to two months before tapering (to avoid exacerbations of hyperthyroidism). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H537905\">",
"    <span class=\"h4\">",
"     Mechanism unknown",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the mechanism of the hyperthyroidism is uncertain or the patient appears to have \"mixed\" type I and type II AIT, a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is reasonable initial therapy. A rapid response suggests type II AIT; the methimazole can then be tapered or stopped. A poor or slow initial response argues for type I AIT. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Treatment if mechanism unknown'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/1\">",
"      Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/2\">",
"      Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem 1989; 35:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/3\">",
"      Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984; 9:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/4\">",
"      Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res 1987; 26:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/5\">",
"      Rao RH, McCready VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab 1986; 62:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/6\">",
"      Franklyn JA, Davis JR, Gammage MD, et al. Amiodarone and thyroid hormone action. Clin Endocrinol (Oxf) 1985; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/7\">",
"      van Beeren HC, Bakker O, Wiersinga WM. Structure-function relationship of the inhibition of the 3,5,3'-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. Endocrinology 1996; 137:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/8\">",
"      Roti E, Minelli R, Gardini E, et al. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid. Arch Intern Med 1993; 153:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/9\">",
"      Braverman LE, Ingbar SH, Vagenakis AG, et al. Enhanced susceptibility to iodide myxedema in patients with Hashimoto's disease. J Clin Endocrinol Metab 1971; 32:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/10\">",
"      Stanbury JB, Ermans AE, Bourdoux P, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 1998; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/11\">",
"      Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/12\">",
"      Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/13\">",
"      Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/14\">",
"      Batcher EL, Tang XC, Singh BN, et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med 2007; 120:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/15\">",
"      Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/16\">",
"      Tsadok MA, Jackevicius CA, Rahme E, et al. Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations. CMAJ 2011; 183:E817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/17\">",
"      Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore) 1983; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/18\">",
"      Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med 1996; 335:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/19\">",
"      Bagchi N, Brown TR, Urdanivia E, Sundick RS. Induction of autoimmune thyroiditis in chickens by dietary iodine. Science 1985; 230:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/20\">",
"      Dunn JT. Guarding our nation's thyroid health. J Clin Endocrinol Metab 2002; 87:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/21\">",
"      Nademanee K, Singh BN, Callahan B, et al. Amiodarone, thyroid hormone indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. Am J Cardiol 1986; 58:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/22\">",
"      Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol (Oxf) 1987; 26:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/23\">",
"      Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest 2001; 24:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/24\">",
"      Nademanee K, Piwonka RW, Singh BN, Hershman JM. Amiodarone and thyroid function. Prog Cardiovasc Dis 1989; 31:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/25\">",
"      Bartalena L, Brogioni S, Grasso L, et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 1996; 81:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/26\">",
"      Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/27\">",
"      Lambert M, Unger J, De Nayer P, et al. Amiodarone-induced thyrotoxicosis suggestive of thyroid damage. J Endocrinol Invest 1990; 13:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/28\">",
"      Bartalena L, Grasso L, Brogioni S, et al. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994; 78:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/29\">",
"      Brennan MD, Erickson DZ, Carney JA, Bahn RS. Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. Thyroid 1995; 5:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/30\">",
"      Bouvy ML, Heerdink ER, Hoes AW, Leufkens HG. Amiodarone-induced thyroid dysfunction associated with cumulative dose. Pharmacoepidemiol Drug Saf 2002; 11:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/31\">",
"      Bogazzi F, Bartalena L, Dell'Unto E, et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol (Oxf) 2007; 67:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/32\">",
"      Yiu KH, Jim MH, Siu CW, et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab 2009; 94:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/33\">",
"      O'Sullivan AJ, Lewis M, Diamond T. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol 2006; 154:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/34\">",
"      Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 2001; 86:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/35\">",
"      Martino E, Bartalena L, Mariotti S, et al. Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. Acta Endocrinol (Copenh) 1988; 119:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/36\">",
"      Eaton SE, Euinton HA, Newman CM, et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 2002; 56:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/37\">",
"      Bogazzi F, Martino E, Dell'Unto E, et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 2003; 26:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/38\">",
"      Piga M, Cocco MC, Serra A, et al. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol 2008; 159:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/39\">",
"      Bogazzi F, Bartalena L, Tomisti L, et al. Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study. J Clin Endocrinol Metab 2011; 96:3374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/40\">",
"      Eskes SA, Endert E, Fliers E, et al. Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. J Clin Endocrinol Metab 2012; 97:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/41\">",
"      Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. Circulation 2002; 105:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/42\">",
"      Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 2010; 95:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/43\">",
"      Martino E, Aghini-Lombardi F, Mariotti S, et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 1986; 9:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/44\">",
"      Dickstein G, Shechner C, Adawi F, et al. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med 1997; 102:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/45\">",
"      Hermida JS, Jarry G, Tcheng E, et al. Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis. Am J Med 2004; 116:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/46\">",
"      Bogazzi F, Miccoli P, Berti P, et al. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. Surgery 2002; 132:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/47\">",
"      Houghton SG, Farley DR, Brennan MD, et al. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg 2004; 28:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/48\">",
"      Tomisti L, Materazzi G, Bartalena L, et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab 2012; 97:3515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/49\">",
"      Bogazzi F, Tomisti L, Rossi G, et al. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. J Clin Endocrinol Metab 2009; 94:3757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/50\">",
"      Uzan L, Guignat L, Meune C, et al. Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. Drug Saf 2006; 29:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/51\">",
"      Bogazzi F, Bartalena L, Tomisti L, et al. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab 2007; 92:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/52\">",
"      Bogazzi F, Bartalena L, Cosci C, et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab 2003; 88:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25065/abstract/53\">",
"      Kurnik D, Loebstein R, Farfel Z, et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7834 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25065=[""].join("\n");
var outline_f24_30_25065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Intrinsic drug effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effects due to iodine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK OF THYROID DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Underlying thyroid function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Normal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Abnormal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dietary iodine intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HYPOTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HYPERTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Types of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Type I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Differentiating the two types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Should amiodarone be discontinued?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H756510\">",
"      - Treatment of type I AIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Thionamides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Radioiodine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Treatment of type II AIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Treatment if mechanism unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PATIENTS ON WARFARIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Predictors of risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H243059672\">",
"      - Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Type I AIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Type II AIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H537905\">",
"      Mechanism unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=related_link\">",
"      Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=related_link\">",
"      Pharmacology and toxicity of thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=related_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_30_25066="Overview of infections following hematopoietic cell transplantation";
var content_f24_30_25066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of infections following hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25066/contributors\">",
"     Elias Anaissie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25066/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/30/25066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/30/25066/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/30/25066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 17, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recipients of allogeneic hematopoietic cell transplants are at increased risk for a variety of infections based upon their degree of immunosuppression and exposures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"     \"Evaluation for infection before hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The types of infections to which these hosts are most vulnerable can be roughly divided based upon the time elapsed since transplantation. The three periods of interest are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preengraftment &mdash; less than three weeks",
"     </li>",
"     <li>",
"      Immediate postengraftment &mdash; three weeks to three months",
"     </li>",
"     <li>",
"      Late postengraftment &mdash; more than three months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This division into time periods is artificial and simplistic but is helpful in the management of the transplant recipient at risk for infection (",
"    <a class=\"graphic graphic_figure graphicRef64491 \" href=\"UTD.htm?4/7/4223\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"UTD.htm?8/10/8362\">",
"     figure 2",
"    </a>",
"    ). By contrast, the autologous transplant recipient is only vulnerable to infection during the pre and immediate postengraftment periods.",
"   </p>",
"   <p>",
"    Patients at each of these times can develop bacterial, fungal, viral or parasitic infections although the specific pathogens tend to cause disease during some of these periods more than others.",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HSCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specific infections to which HCT recipients are most susceptible will be reviewed here for each of the three periods. The discussion will include the clinical syndromes caused by these infections as well as by noninfectious causes (",
"    <a class=\"graphic graphic_table graphicRef50318 graphicRef63086 \" href=\"UTD.htm?12/63/13310\">",
"     table 1A-B",
"    </a>",
"    ). A summary of infections in the solid organ transplant recipient is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     IDSA/CDC",
"    </span>",
"    clinical practice guidelines for preventing opportunistic infections in patients following HSCT, as well as other IDSA guidelines, can be accessed through the IDSA's web site [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for infection and the evaluation of infection before HCT are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"     \"Evaluation for infection before hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREENGRAFTMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major risk factors for infection during the preengraftment period in the first three weeks after HCT are mucositis and cutaneous damage, which disrupt the natural barriers of the skin and mucous membranes, neutropenia with resulting loss of phagocytic abilities, and organ dysfunction (",
"    <a class=\"graphic graphic_table graphicRef74989 graphicRef54989 graphicRef67849 \" href=\"UTD.htm?37/52/38733\">",
"     table 2A-C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78377 graphicRef53314 graphicRef76752 \" href=\"UTD.htm?26/63/27646\">",
"     table 3A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerobic gram-positive and gram-negative bacteria account for most documented infections during this granulocytopenic period [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/3\">",
"     3",
"    </a>",
"    ]. Gram-positive organisms include coagulase-negative staphylococci, Staphylococcus aureus, viridans streptococci, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/4\">",
"     4",
"    </a>",
"    ]. Important risk factors for bacterial infections are neutropenia and mucocutaneous damage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/2\">",
"     2",
"    </a>",
"    ]. A rapidly fatal streptococcal shock syndrome can occur in a small subset of patients with infection by viridans streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A group from Hong Kong hypothesized that cell-wall deficient bacteria (usually gram-positive) might be responsible for episodes of febrile neutropenia following HCT in which blood cultures were negative; twenty such cases were identified among 86 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/8\">",
"     8",
"    </a>",
"    ]. Bacillus spp were the most common cell-wall deficient organisms in this study (10 of 20 cases); 16 of the 20 patients had received beta-lactams or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    within 10 days of the bacteremia.",
"   </p>",
"   <p>",
"    Diarrhea commonly occurs among patients who have undergone HCT due to both infectious and noninfectious agents. The most common cause of infectious diarrhea in patients undergoing HCT is Clostridium difficile-associated diarrhea. The frequency of C. difficile associated diarrhea is illustrated by a study of 135 HCT patients who developed diarrhea either before or after engraftment and were tested for C. difficile toxin A, 21 (16 percent) were positive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gram-negative infections may be caused by Legionella spp, Pseudomonas aeruginosa, Enterobacteriaceae, and Stenotrophomonas maltophilia, and other bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/10\">",
"     10",
"    </a>",
"    ]. The most common sites of bacterial infection include those involving the bloodstream and the lungs, eg, bacteremia and pneumonia. Less frequent manifestations include septic shock, the acute respiratory distress syndrome, and neutropenic enterocolitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic transplant recipients are at a significantly higher risk for fungal infection than those receiving autologous marrow stem cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Candida",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of antifungal prophylaxis with triazole antimicrobials, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , has significantly reduced the morbidity and mortality of invasive candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, the incidence of infection with triazole-resistant Candida spp, such as C. krusei and C. glabrata, has increased, probably as a result of this prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. One study of allogeneic HCT recipients who received either 75 days of prophylactic fluconazole or placebo found after eight years of follow-up that the incidence of invasive candidiasis, early and late mortality from candidiasis, and the occurrence of severe gastrointestinal graft-versus-host disease were all higher among placebo recipients compared to those who received lengthy fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, high (400 mg) versus low (200 mg) dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis until neutrophil recovery was compared in 253 HCT recipients in one center [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/17\">",
"     17",
"    </a>",
"    ]. The incidence of colonization, superficial, and systemic candidiasis did not differ between the groups, although therapy was changed to an alternate regimen, usually amphotericin B, in 60 and 59 percent of the patients at a median of 10 and 11 days, respectively, for persistent fever.",
"   </p>",
"   <p>",
"    Risk factors for invasive candidiasis include severe neutropenia, use of broad-spectrum antibiotics, organ dysfunction, mucocutaneous damage, and yeast colonization with Candida spp [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Candidal infections can either be localized (gastrointestinal tract [eg, thrush, esophagitis], or genital area) or disseminated (acute followed in some instances by chronic infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/22\">",
"     22",
"    </a>",
"    ]. Skin lesions, usually erythematous and maculopapular in nature, can be the first evidence of disseminated candidiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Molds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections caused by molds (Aspergillus, Fusarium, Zygomycetes, and the agents of hyalohyphomycosis and phaeohyphomycosis) may also occur during this phase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Risk factors for non-candidal fungal infections include allogeneic HCT transplantation, positive pretransplant serology for cytomegalovirus (CMV), and delayed engraftment. None of these factors were independently significant in the autologous recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major clinical manifestation of infection with these molds is pulmonary infection. However, involvement of the sinuses, central nervous system (CNS), and skin may also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major viruses encountered during the immediate posttransplant period are herpes simplex virus (HSV) which reactivates and respiratory viruses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all HSV infections in HCT recipients are caused by viral reactivation; thus, only seropositive patients are at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate of reactivation is more than 70 percent and appears to be comparable after autologous or allogeneic transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/25\">",
"     25",
"    </a>",
"    ]. The median time to onset of HSV disease is two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV-1 infections primarily present as severe mucositis and occasionally esophagitis. Rarely, HCT recipients develop HSV-1 viremia, which can lead to secondary viral infection of organs including: the trachea (erosive tracheobronchitis), lungs, liver, CNS, adrenal glands, or gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Erosive tracheobronchitis and pneumonitis can also arise via contiguous spread from the oropharynx.",
"   </p>",
"   <p>",
"    Reactivation of HSV-2 infection in the genital or perineal area accounts for only 10 to 15 percent of all HSV infections in HCT patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/29\">",
"     29",
"    </a>",
"    ]. Prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    has markedly reduced the incidence of all herpetic infections in transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Respiratory viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common respiratory viruses include respiratory syncytial virus (RSV), the parainfluenza viruses, rhinoviruses, and influenza A and B. The frequency and timing of the isolation of these viruses generally reflects the pattern found concomitantly in the community and often varies from year to year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. These infections are seen both in allogeneic and autologous recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/34\">",
"     34",
"    </a>",
"    ]. Emerging data also suggest that human metapneumovirus infection needs to be considered in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection with RSV occurs in more than 50 percent of HCT recipients but usually is not a severe illness [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/31\">",
"     31",
"    </a>",
"    ]. However, outbreaks of fatal infections have been linked to this virus in transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/32,35,36\">",
"     32,35,36",
"    </a>",
"    ]. The role of RSV in these fatal outcomes remains to be determined. RSV infections in HCT recipients with RSV infections usually develop upper respiratory tract symptoms (eg, rhinorrhea, sinus congestion, sore throat, and otitis media), which almost always precede lower respiratory tract infection (tracheobronchitis, pneumonia) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission of parainfluenza and influenza viruses is by direct droplet spread or aerosolized respiratory secretions. During community outbreaks, influenza, especially type A, and parainfluenza viruses have been reported as a frequent cause of severe and fatal pneumonia in HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The exact role played by these viruses in these fatal infections is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMMEDIATE POSTENGRAFTMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major risk factors for infection during the immediate postengraftment period three weeks to three months after HCT are mucositis and cutaneous damage, similar to preengraftment, but also cellular immune dysfunction, immunomodulating viruses, hyposplenism, decrease in opsonization, and diminished reticuloendothelial function. For allogeneic HCT recipients, additional risk factors include acute graft versus host disease (GVHD) and its therapy (",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"UTD.htm?8/10/8362\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial pathogens deserving special attention during this period are Listeria monocytogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/38\">",
"     38",
"    </a>",
"    ] and Legionella pneumophila [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive aspergillosis can occur among both allogeneic and autologous HCT recipients although the incidence is more frequent among the former (5 to 30 versus 1 to 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. The median time of onset of aspergillosis is 100 days after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/45\">",
"     45",
"    </a>",
"    ]. Risk factors for aspergillosis include older age, the presence and severity of GVHD, corticosteroid therapy, graft failure, diagnosis other than chronic myeloid leukemia, advanced cancer at transplantation, cytopenias (neutropenia, lymphopenia, monocytopenia) and iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Risk factors associated with early invasive mold infections following allogeneic stem cell transplantation (&lt;40 days) include older age and human leukocyte antigen match, whereas variables associated with late disease (&ge;40 days following HCT) include GVHD and cytomegalovirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been increasing recognition of the less common but fatal opportunistic mycoses in transplant recipients, including those caused by Fusarium spp, the Zygomycetes, resistant species of Candida [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/23,44,48-52\">",
"     23,44,48-52",
"    </a>",
"    ], Pseudallescheria boydii (also known as Scedosporium apiospermum, which is the asexual form of P. boydii), and others. The clinical features of these infections often mimic aspergillosis, although fusariosis has some unique manifestations, which include skin lesions and bloodstream infections [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/23,48\">",
"     23,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic disseminated candidiasis is now rarely seen in HCT recipients since the introduction of triazole prophylaxis. The development of fever, abdominal symptoms, and increasing alkaline phosphatase in a patient who has recently recovered from neutropenia and had not received appropriate antifungal prophylaxis should prompt an investigation for hepatosplenic candidiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pneumocystis carinii (jirovecii) pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median time to onset of PCP is nine weeks after HCT. However, this pathogen now accounts for less than 1 to 2 percent of pneumonias in transplant recipients with routine use of effective chemoprophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunomodulating viruses as well as viruses encountered in the community play a role in viral infections in the immediate postengraftment period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the routine use of prophylactic regimens, CMV seropositive allogeneic HCT recipients had a 70 to 80 percent risk of reactivation of this virus, and one-third of these patients developed CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/54\">",
"     54",
"    </a>",
"    ]. By comparison, CMV reactivation occurred in only 40 percent of autologous or syngeneic HCT recipients; CMV disease, mainly pneumonia, evolved in fewer than 5 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. The risk of acquiring CMV from either blood transfusion or seropositive marrow in CMV seronegative HCT recipients was also approximately 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for symptomatic CMV disease include CMV seropositive recipient, high titer of virus, allogeneic HCT especially from a matched unrelated donor (MUD), advanced age, use of total body irradiation for conditioning, acute GVHD, and the use of CD34+ selected allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/60-64\">",
"     60-64",
"    </a>",
"    ]. There does not appear to be a difference between the incidence of CMV disease after allogeneic bone marrow transplantation compared with allogeneic peripheral blood transplantation.",
"   </p>",
"   <p>",
"    CMV infections in HCT recipients most commonly present as fever of unknown origin, interstitial pneumonitis, or enteritis; less often these patients can develop retinitis, encephalitis, hepatitis, or bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/60-65\">",
"     60-65",
"    </a>",
"    ]. Preemptive antiviral therapy has markedly reduced the incidence and severity of CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/66,67\">",
"     66,67",
"    </a>",
"    ] and delayed its onset from a median of eight weeks to greater than three months. However, some investigators have found an ongoing risk of late CMV disease despite preemptive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study found an increased mortality rate from both bacterial and fungal infections in CMV-seronegative HCT recipients from a CMV-seropositive donor, even after controlling for neutropenia due to ganciclovir and the occurrence of CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/70\">",
"     70",
"    </a>",
"    ]. The cumulative mortality at one year after HCT was 18.3 and 9.7 percent for CMV-seronegative recipients of HCT from a CMV-seropositive donor and seronegative recipients from seronegative donors, respectively. The investigators speculate about an immunomodulatory effect of primary CMV infection in HCT recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Human herpesviruses 6, 7, and 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus-6 (HHV-6) reactivation has been documented in 40 to 60 percent of HCT recipients, usually three weeks after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. However, the clinical significance of this reactivation remains to be determined. Clinical syndromes associated with HHV-6 reactivation include rash, fever, interstitial pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/74\">",
"     74",
"    </a>",
"    ], encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], and bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The administration of anti-CD3 monoclonal antibodies has been associated with a higher likelihood of reactivating HHV-6 and with a higher probability of encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/77\">",
"     77",
"    </a>",
"    ]. GVHD also appears to be a risk factor for HHV-6 reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/72\">",
"     72",
"    </a>",
"    ]. On the other hand, HHV-6 is immunosuppressive and may predispose patients to other viral infections such as CMV and Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery of HHV-7 DNA in peripheral blood leukocytes during the early posttransplant period has been associated with a longer time to neutrophil engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/79\">",
"     79",
"    </a>",
"    ]. However, the exact role of this virus in causing disease is unknown.",
"   </p>",
"   <p>",
"    The prevalence and incidence of HHV-8 infections after allogeneic HCT was evaluated by serologic testing in 187 donor-recipient pairs in Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/80\">",
"     80",
"    </a>",
"    ]. Before transplantation, 24 (13 percent) of the donors and 20 (11 percent) of the recipients were seropositive for HHV-8. Seroconversion occurred in 19 (11 percent). The relative risk of seroconversion after transplantation secondary to an HHV-8 seropositive donor was 2.96 (95 percent CI 1.21-7.25) compared to a seronegative donor. No HHV-8 related complications were documented after a median follow-up of six years.",
"   </p>",
"   <p>",
"    HHV-8 reactivation uncommonly occurs in HCT recipients in association with clinical events such as fever, cutaneous rash, liver enzyme dysfunction, and bone marrow aplasia. The relationship of HHV-8 reactivation to these events is not established [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary EBV infection presenting with pneumonia was reported in a HCT recipient one month following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/82\">",
"     82",
"    </a>",
"    ]. The virus must have been transmitted by the donor's bone marrow as the transplant recipient had negative serologic tests for EBV before transplantation and the donor's bone marrow was positive for EBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Adenovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of adenovirus infection occurs in greater than 80 percent of autologous and allogeneic HCT recipients but causes severe disease in fewer than two percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/83\">",
"     83",
"    </a>",
"    ]. The timing of reactivation differs for children and adults. Adenovirus reactivation develops within 30 days in children but typically more than 90 days following transplantation in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Transmission of infection may occur by respiratory droplets or the oral-fecal route. A donor-to-recipient transmission has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/84\">",
"     84",
"    </a>",
"    ]. The most important risk factor for adenoviral disease is acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/84,86\">",
"     84,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are four clinically significant adenoviral syndromes: pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/84,86\">",
"     84,86",
"    </a>",
"    ], nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/86,87\">",
"     86,87",
"    </a>",
"    ], diarrhea and hemorrhagic colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/88\">",
"     88",
"    </a>",
"    ], and hemorrhagic cystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/84\">",
"     84",
"    </a>",
"    ]. Disseminated disease with multiorgan failure can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/83\">",
"     83",
"    </a>",
"    ]. Asymptomatic nasopharyngeal carriage and adenovirus hepatitis have been reported infrequently [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/84,89\">",
"     84,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Enteric viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virus infections of the enteric system (eg, coxsackie, echo, and rotaviruses) are most prevalent during the summer and fall months. Infection is usually transmitted by the fecal-oral route. Enteric virus infections among HCT recipients may cause gastroenteritis (coxsackie A [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/90,91\">",
"     90,91",
"    </a>",
"    ], rotavirus, and norovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/92\">",
"     92",
"    </a>",
"    ]) but may also involve other organ systems including the lungs, cardiovascular, and CNS (echovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/93\">",
"     93",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43241?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses\", section on 'Immunocompromised hosts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Respiratory viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with RSV, influenza and parainfluenza, and rhinovirus continue to occur during the immediate postengraftment period (",
"    <a class=\"graphic graphic_figure graphicRef64491 \" href=\"UTD.htm?4/7/4223\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52716 \" href=\"UTD.htm?8/10/8362\">",
"     figure 2",
"    </a>",
"    ). Another emerging pathogen in this category is human metapneumovirus (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Parasitic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of parasitic infections after HCT frequently requires unique exposures, with the exception of toxoplasmosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of toxoplasmosis occurs in 5 to 15 percent of T cell depleted or otherwise severely immunosuppressed allogeneic transplant recipients; in other transplant recipients the incidence is less then 1 percent. The infection typically develops in the second month after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/94,95\">",
"     94,95",
"    </a>",
"    ], among patients seropositive prior to HCT. Patients with reactivation toxoplasmosis commonly have neurologic deficits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures, although disseminated disease is also frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/65,96-98\">",
"     65,96-98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other parasitic infections are rare and include strongyloidiasis and cryptosporidiosis. Leishmaniasis and trypanosomiasis can occur in endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mycobacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterial infections in transplant recipients are rare, occurring in one to three percent of allogeneic and 0.2 percent of autologous HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. Infection can arise due to reactivation (Mycobacterium tuberculosis and Mycobacterium avium complex) or new exposure (atypical mycobacteria).",
"   </p>",
"   <p>",
"    The most frequent manifestation of tuberculosis is pulmonary infection, which tends to occur during the first three months. Extrapulmonary disease, such as bloodstream, catheter-related, soft tissue, bone and joint infections, is more common with atypical mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/100-102\">",
"     100-102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LATE POSTENGRAFTMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late infectious complications are typically only seen among allogeneic recipients. The major risk factor for infection during this period is chronic GVHD and its therapy, resulting in (",
"    <a class=\"graphic graphic_table graphicRef74989 graphicRef54989 graphicRef67849 \" href=\"UTD.htm?37/52/38733\">",
"     table 2A-C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78377 graphicRef53314 graphicRef76752 \" href=\"UTD.htm?26/63/27646\">",
"     table 3A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucocutaneous damage",
"     </li>",
"     <li>",
"      Immunodeficiency (eg, cellular and humoral immune dysfunction, hyposplenism, decrease in opsonization, and diminished reticuloendothelial function).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late bacteremia is not uncommon after allogeneic HCT and is typically caused by the encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/103-105\">",
"     103-105",
"    </a>",
"    ], staphylococci and gram-negative bacteria, such as Pseudomonas spp [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/106\">",
"     106",
"    </a>",
"    ]. Pneumonia and meningitis are among the complications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/65,105\">",
"     65,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of pneumococcal infection is greater among patients with severe chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/105,107\">",
"     105,107",
"    </a>",
"    ], immunoglobulin deficiency (usually in subclasses IgG2 and IgG4) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/108\">",
"     108",
"    </a>",
"    ], and hyposplenism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. In a review of 47 HCT recipients who developed 54 pneumococcal infections, 50 infections occurred late at a mean of 473 days after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/105\">",
"     105",
"    </a>",
"    ]. Bacteremic pneumonia was the most common manifestation, but isolated pneumonia and bacteremia also occurred. Infection occurred in five patients despite pneumococcal vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella zoster virus (VZV), EBV, and viruses to which the transplant recipient may have lost immunity figure more prominently as infections during this late postengraftment period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Varicella zoster virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of VZV reactivation is approximately equal among allogeneic and autologous HCT recipients (20 to 40 percent). VZV infection tends be more common among children (up to 90 percent by year one) and to occur earlier posttransplantation (median 100 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/111\">",
"     111",
"    </a>",
"    ]. Infection typically occurs during the first six to nine months (80 percent during first year) and may be associated with complications including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cutaneous dissemination &mdash; 25 percent",
"     </li>",
"     <li>",
"      Post-herpetic neuralgia &mdash; 25 percent",
"     </li>",
"     <li>",
"      Scarring &mdash; 20 percent",
"     </li>",
"     <li>",
"      Bacterial superinfection &mdash; 15 percent",
"     </li>",
"     <li>",
"      Death &mdash; 5 percent",
"     </li>",
"     <li>",
"      CNS manifestations &mdash; &lt;2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dissemination following allogeneic HCT appears to be more common than for autologous transplantation HCT (45 versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/112\">",
"     112",
"    </a>",
"    ]. In addition to skin, dissemination may involve the lungs, liver, and CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. In HCT recipients, VZV lesions last longer (10 to 14 days) and heal more slowly (3 to 4 weeks) than in normal adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunocompromised patients can also uncommonly develop varicella-like skin lesions with no primary dermatomal eruption; a syndrome termed atypical generalized zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/115\">",
"     115",
"    </a>",
"    ]. Thrombocytopenia and disseminated intravascular coagulation have also been reported. Durable immunity seems to develop following this type of VZV infection, since fewer than five percent of patients have a second episode [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk factors for VZV reactivation include: VZV seropositivity or VZV infection prior to HCT, intensive antirejection therapy (pretransplant irradiation, and post transplant use of anti-thymocyte globulin), and hematologic cancer other than chronic myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/113,114,116\">",
"     113,114,116",
"    </a>",
"    ]. VZV-specific cell-mediated immune responses (usually suppressed after HCT) inversely correlate with the risk of VZV infection. By contrast, no correlation exists between pretransplant VZV IgG antibodies and posttransplant reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/117\">",
"     117",
"    </a>",
"    ]. GVHD is also likely to be a significant predisposing factor. Acute GVHD, absolute lymphopenia, and intensive antirejection therapy have been associated with severe and disseminated VZV disease and death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/112,118\">",
"     112,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    therapy may reduce the risk of VZV infection after allogeneic HCT. In a randomized, placebo-controlled trial of 77 HCT recipients, acyclovir (800 mg twice daily) from one to two months after HCT until one year was associated with a significant reduction in VZV infection at one year (5 versus 26 percent, hazard ratio 0.16, 95% CI 0.04-0.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although EBV infection in HCT recipients is very common (almost universal in the EBV seronegative recipient who receives a seropositive bone marrow) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/120\">",
"     120",
"    </a>",
"    ], the incidence of disease is rather low [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/121\">",
"     121",
"    </a>",
"    ]. The median time to onset is between three to five months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spectrum of EBV infection includes increased oropharyngeal EBV excretion, a non-specific viral syndrome consisting of fever and neutropenia, oral hairy leukoplakia, aplastic anemia, meningoencephalitis, and posttransplant lymphoproliferative disorder (PTLD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PTLD arises from the failure of immune surveillance by EBV-specific T lymphocytes resulting in a polyclonal or less often monoclonal B cell proliferation, usually of donor origin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/124-127\">",
"     124-127",
"    </a>",
"    ]. The incidence of PTLD varies from &lt;1 percent of matched related allogeneic HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/128\">",
"     128",
"    </a>",
"    ] to up to 18 percent among high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/129\">",
"     129",
"    </a>",
"    ]. High-risk patients include allogeneic recipients of matched unrelated, mismatched, or T-cell depleted transplants and recipients of high dose antithymocyte globulin or anti-T cell monoclonal antibodies as GVHD prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/121,129,130\">",
"     121,129,130",
"    </a>",
"    ]. Chronic GVHD is an additional risk factor for PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/128\">",
"     128",
"    </a>",
"    ]. T cell depletion is the only predisposing factor for PTLD in the autologous transplant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/131\">",
"     131",
"    </a>",
"    ]. Increases in EBV viral load following HCT are common, and are highest in patients at risk for PTLD, suggesting that quantitative viral load surveillance may identify high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/132\">",
"     132",
"    </a>",
"    ]. Antibody levels are unreliable [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/132-134\">",
"     132-134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pace of PTLD ranges from indolent to fulminant, and the extent of disease varies from localized nodular lesions to widely disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/122,129\">",
"     122,129",
"    </a>",
"    ]. An infectious mononucleosis-like syndrome may be an early presentation of PTLD. Late manifestations include gastrointestinal tract involvement (25 percent) with risk for bleeding and perforation, and CNS involvement (10 percent). Rarely, PTLD may present as plasmacytoma and circulating paraproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/135,136\">",
"     135,136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Other viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients lose their specific B cell immunity to viruses such as measles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/137\">",
"     137",
"    </a>",
"    ], mumps, rubella, parvovirus B19, and",
"    <span class=\"nowrap\">",
"     BK/JC",
"    </span>",
"    virus, but severe disease with these viruses is rare. Manifestations of these viral infections in HCT recipients can include severe anemia (parvovirus B19) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/138\">",
"     138",
"    </a>",
"    ], late-onset, prolonged hemorrhagic cystitis, transient hepatic dysfunction, and progressive multifocal leukoencephalopathy",
"    <span class=\"nowrap\">",
"     (BK/JC",
"    </span>",
"    virus) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/139-142\">",
"     139-142",
"    </a>",
"    ]. BK viruria (reactivation of latent infection) occurs in approximately 50 and less than 10 percent of allogeneic and autologous HCT recipients, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human herpesvirus (HHV)-8 was reported to cause bone marrow failure as a late complication in a patient receiving an autologous HCT for lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/143\">",
"     143",
"    </a>",
"    ]. The patient was seropositive for the virus prior to receiving his own bone marrow cells and died 151 days after transplantation.",
"   </p>",
"   <p>",
"    One case of herpes simplex encephalitis was reported in a patient more than seven months after allogenic transplantation for chronic myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/65\">",
"     65",
"    </a>",
"    ]. The patient survived, but with neuropsychologic sequelae.",
"   </p>",
"   <p>",
"    Reactivation of hepatitis B and C viruses after HCT appears to be common (50 to 70 percent), although probably a benign infection. However, primary infection with these viruses is uncommon (2 to 9 percent). The long-term pathology caused by these viruses in patients undergoing HCT remains to be defined [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/144,145\">",
"     144,145",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     INFECTIONS IN SPECIAL SITUATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the infections described above apply to all HCT recipients, infection may be more common in some hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Asplenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have functional asplenia following HCT or those with previous splenectomy are at risk for infections due to the absence of the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/109\">",
"     109",
"    </a>",
"    ]. These include infections caused by encapsulated bacteria (such as S. pneumoniae, H. influenzae, Neisseria spp, and Capnocytophaga canimorsus) and in certain geographic areas by intraerythrocytic parasites (such as Babesia microti).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Hypoglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma and chronic lymphocytic leukemia show declining immunoglobulin levels with progression of the disease and especially following allogeneic HCT. Pneumonia, urinary tract, and skin infections caused by encapsulated microorganisms and gram-negative bacilli (eg, Escherichia coli) are most frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/146-149\">",
"     146-149",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Exposure to purine analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with purine analogues such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    , 2-chloroxyadenosine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    has added a new spectrum of infections typically associated with T-cell dysfunction. These include fungal, viral (especially VZV, CMV, HSV), mycobacterial, bacterial (L. monocytogenes), and protozoal (PCP) infections. Listeriosis and PCP may be particularly important if patients are receiving concomitant corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?24/30/25066/abstract/150-154\">",
"     150-154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Environmental risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT recipients can encounter unusual pathogens in the environment related to travel, food and water, or pets (",
"    <a class=\"graphic graphic_table graphicRef51914 \" href=\"UTD.htm?17/30/17900\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Acute management of the febrile stem cell transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;All febrile HCT recipients should be treated empirically with broad-spectrum antibiotics. The choice of empiric therapy should depend upon the risk group (high or low risk for complications), the potential sites of infection, the susceptibility patterns at a given institution, and the cost of the various regimens. The approach can be based upon the risk for complications in a given patient (",
"    <a class=\"graphic graphic_table graphicRef51151 \" href=\"UTD.htm?16/14/16619\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed May 5, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/2\">",
"      Wingard JR. Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 1990; 6:371.",
"     </a>",
"    </li>",
"    <li>",
"     Wingard, JR. Prevention and treatment of bacterial and fungal infections. In: Hospital Infections, Forman, SJ, Blume, KG, Thomas, ED (Eds). Blackwell Scientific, Boston 1994. p.363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/4\">",
"      Conterno LO, Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998; 19:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/5\">",
"      Kern W, Kurrle E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection 1990; 18:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/6\">",
"      Awada A, van der Auwera P, Meunier F, et al. Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis 1992; 15:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/7\">",
"      Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994; 97:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/8\">",
"      Woo PC, Wong SS, Lum PN, et al. Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. Lancet 2001; 357:675.",
"     </a>",
"    </li>",
"    <li>",
"     Arango, JI, Restrepo, A, Schneider, DL, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006;.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/10\">",
"      Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg 1997; 87:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/11\">",
"      Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/12\">",
"      Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/13\">",
"      Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/14\">",
"      Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/15\">",
"      Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/16\">",
"      Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/17\">",
"      MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/18\">",
"      Rossetti F, Brawner DL, Bowden R, et al. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995; 20:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/19\">",
"      Vazquez JA, Dembry LM, Sanchez V, et al. Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol 1998; 36:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/20\">",
"      Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/21\">",
"      Zollner-Schwetz I, Auner HW, Paulitsch A, et al. Oral and intestinal Candida colonization in patients undergoing hematopoietic stem-cell transplantation. J Infect Dis 2008; 198:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/22\">",
"      Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/23\">",
"      Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/24\">",
"      Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994; 96:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/25\">",
"      Wingard JR. Infections in allogeneic bone marrow transplant recipients. Semin Oncol 1993; 20:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/26\">",
"      Prentice HG, Hann IM. Antiviral therapy in the immunocompromised patient. Br Med Bull 1985; 41:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/27\">",
"      Johnson JR, Egaas S, Gleaves CA, et al. Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin Infect Dis 1992; 14:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/28\">",
"      Ramsey PG, Fife KH, Hackman RC, et al. Herpes simplex virus pneumonia: clinical, virologic, and pathologic features in 20 patients. Ann Intern Med 1982; 97:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/29\">",
"      Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994; 18:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/30\">",
"      Epstein JB, Ransier A, Sherlock CH, et al. Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Eur J Cancer B Oral Oncol 1996; 32B:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/31\">",
"      Ljungman P, Gleaves CA, Meyers JD. Respiratory virus infection in immunocompromised patients. Bone Marrow Transplant 1989; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/32\">",
"      Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/33\">",
"      Wendt CH, Weisdorf DJ, Jordan MC, et al. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992; 326:921.",
"     </a>",
"    </li>",
"    <li>",
"     Ljungman, P, Ward, K, Crooks, B, et al. In: 25th annual meeting European group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/35\">",
"      Jones BL, Clark S, Curran ET, et al. Control of an outbreak of respiratory syncytial virus infection in immunocompromised adults. J Hosp Infect 2000; 44:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/36\">",
"      Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/37\">",
"      Sparrelid E, Ljungman P, Ekel&ouml;f-Andstr&ouml;m E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997; 19:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/38\">",
"      Chang J, Powles R, Mehta J, et al. Listeriosis in bone marrow transplant recipients: incidence, clinical features, and treatment. Clin Infect Dis 1995; 21:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/39\">",
"      Harrington RD, Woolfrey AE, Bowden R, et al. Legionellosis in a bone marrow transplant center. Bone Marrow Transplant 1996; 18:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/40\">",
"      Jantunen E, Ruutu P, Piilonen A, et al. Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000; 26:759.",
"     </a>",
"    </li>",
"    <li>",
"     Fetscher, S, Technau, K, Lange, W. Aspergillosis after high-dose chemotherapy and autologous stem cell transplantation. In: 25th annual meeting European group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/42\">",
"      Iwen PC, Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol 1993; 14:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/43\">",
"      Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/44\">",
"      Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/45\">",
"      Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/46\">",
"      Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/47\">",
"      Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/48\">",
"      Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/49\">",
"      Anaissie E, Bodey GP. Disseminated trichosporonosis: meeting the challenge. Eur J Clin Microbiol Infect Dis 1991; 10:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/50\">",
"      Anaissie E, Bodey GP. Nosocomial fungal infections. Old problems and new challenges. Infect Dis Clin North Am 1989; 3:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/51\">",
"      Anaissie E, Bodey GP, Kantarjian H, et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989; 11:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/52\">",
"      Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore) 1993; 72:78.",
"     </a>",
"    </li>",
"    <li>",
"     Cordonnier, C, Einsele, H, Beaume, J, et al. Management and incidence of Pneumocystis carinii pneumonia after stem cell transplant: A survey in the EBMT centers. In: 25th annual meeting European group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/54\">",
"      Gluckman E, Traineau R, Devergie A, et al. Prevention and treatment of CMV infection after allogeneic bone marrow transplant. Ann Hematol 1992; 64 Suppl:A158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/55\">",
"      Wingard JR, Chen DY, Burns WH, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/56\">",
"      Ljungman P, Biron P, Bosi A, et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 13:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/57\">",
"      Boeckh M, Gooley TA, Reusser P, et al. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995; 172:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/58\">",
"      Meyers JD. Prevention and treatment of cytomegalovirus infections with interferons and immune globulins. Infection 1985; 13 Suppl 2:S211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/59\">",
"      Boeckh M, Bowden RA, Goodrich JM, et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/60\">",
"      Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993; 55:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/61\">",
"      Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990; 162:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/62\">",
"      Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/63\">",
"      Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/64\">",
"      Limaye AP, Huang ML, Leisenring W, et al. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis 2001; 183:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/65\">",
"      Denier C, Bourhis JH, Lacroix C, et al. Spectrum and prognosis of neurologic complications after hematopoietic transplantation. Neurology 2006; 67:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/66\">",
"      Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86:2815.",
"     </a>",
"    </li>",
"    <li>",
"     Dentamaro, T, Cudillo, L, Picardi, A, et al. Preemptive therapy of CMV infection in allogeneic hematopoietic stem cell transplantation. In: 25th annual meeting European group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/68\">",
"      Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/69\">",
"      Wolf DG, Lurain NS, Zuckerman T, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 2003; 101:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/70\">",
"      Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/71\">",
"      Kadakia MP, Rybka WB, Stewart JA, et al. Human herpesvirus 6: infection and disease following autologous and allogeneic bone marrow transplantation. Blood 1996; 87:5341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/72\">",
"      Wilborn F, Schmidt CA, Zimmermann R, et al. Detection of herpesvirus type 6 by polymerase chain reaction in blood donors: random tests and prospective longitudinal studies. Br J Haematol 1994; 88:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/73\">",
"      Yoshikawa T. Human herpesvirus 6 infection in hematopoietic stem cell transplant patients. Br J Haematol 2004; 124:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/74\">",
"      Cone RW, Huang ML, Hackman RC. Human herpesvirus 6 and pneumonia. Leuk Lymphoma 1994; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     Engelhard, D, Cordonnier, C, Einsele, H, et al. HHV-6 disease following BMT and PBSCT preliminary report of an EBMT survey. In: 25th annual meeting European group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/76\">",
"      Seeley WW, Marty FM, Holmes TM, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology 2007; 69:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/77\">",
"      Zerr DM, Gooley TA, Yeung L, et al. Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 33:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/78\">",
"      Imbert-Marcille BM, Tang XW, Lepelletier D, et al. Human herpesvirus 6 infection after autologous or allogeneic stem cell transplantation: a single-center prospective longitudinal study of 92 patients. Clin Infect Dis 2000; 31:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/79\">",
"      Chan PK, Peiris JS, Yuen KY, et al. Human herpesvirus-6 and human herpesvirus-7 infections in bone marrow transplant recipients. J Med Virol 1997; 53:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/80\">",
"      Gentile G, Capobianchi A, Volpi A, et al. Human herpesvirus 8 DNA in serum during seroconversion in allogeneic bone marrow transplant recipients. J Natl Cancer Inst 2005; 97:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/81\">",
"      Luppi M, Barozzi P, Schulz TF, et al. Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood 2000; 96:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/82\">",
"      Teira P, Agbalika F, Bergeron A, et al. Primary Epstein-Barr virus infection with pneumonia transmitted by allogeneic bone marrow after transplantation. Clin Infect Dis 2006; 43:892.",
"     </a>",
"    </li>",
"    <li>",
"     Guenther, A, Schmidt, B, Rosler, W, et al. A prospective study of adenovirus infections in BMT/PBSCT. In: 25th annual meeting European group for blood and Marrow Transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/84\">",
"      Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/85\">",
"      Wasserman R, August CS, Plotkin SA. Viral infections in pediatric bone marrow transplant patients. Pediatr Infect Dis J 1988; 7:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/86\">",
"      Shields AF, Hackman RC, Fife KH, et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985; 312:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/87\">",
"      Liles WC, Cushing H, Holt S, et al. Severe adenoviral nephritis following bone marrow transplantation: successful treatment with intravenous ribavirin. Bone Marrow Transplant 1993; 12:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/88\">",
"      Johnson PR, Yin JA, Morris DJ, et al. Fulminant hepatic necrosis caused by adenovirus type 5 following bone marrow transplantation. Bone Marrow Transplant 1990; 5:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/89\">",
"      Bertheau P, Parquet N, Ferchal F, et al. Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 17:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/90\">",
"      Townsend TR, Bolyard EA, Yolken RH, et al. Outbreak of Coxsackie A1 gastroenteritis: a complication of bone-marrow transplantation. Lancet 1982; 1:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/91\">",
"      Yolken RH, Bishop CA, Townsend TR, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 1982; 306:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/92\">",
"      Roddie C, Paul JP, Benjamin R, et al. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis 2009; 49:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/93\">",
"      Biggs DD, Toorkey BC, Carrigan DR, et al. Disseminated echovirus infection complicating bone marrow transplantation. Am J Med 1990; 88:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/94\">",
"      Hirsch R, Burke BA, Kersey JH. Toxoplasmosis in bone marrow transplant recipients. J Pediatr 1984; 105:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/95\">",
"      Shepp DH, Hackman RC, Conley FK, et al. Toxoplasma gondii reactivation identified by detection of parasitemia in tissue culture. Ann Intern Med 1985; 103:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/96\">",
"      Picardi M, De Rosa G, Di Salle F, et al. Post-transplant cerebral toxoplasmosis diagnosed by magnetic resonance imaging. Haematologica 1998; 83:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/97\">",
"      Chandrasekar PH, Momin F. Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of the literature. Bone Marrow Transplant Team. Bone Marrow Transplant 1997; 19:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/98\">",
"      Peacock JE Jr, Greven CM, Cruz JM, Hurd DD. Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Bone Marrow Transplant 1995; 15:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/99\">",
"      Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis 2007; 44:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/100\">",
"      Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant 1997; 19:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/101\">",
"      Navari RM, Sullivan KM, Springmeyer SC, et al. Mycobacterial infections in marrow transplant patients. Transplantation 1983; 36:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/102\">",
"      Kurzrock R, Zander A, Vellekoop L, et al. Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med 1984; 77:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/103\">",
"      Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995; 86:3979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/104\">",
"      Hoyle C, Goldman JM. Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. Bone Marrow Transplant 1994; 14:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/105\">",
"      Youssef S, Rodriguez G, Rolston KV, et al. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore) 2007; 86:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/106\">",
"      Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/107\">",
"      Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95:3683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/108\">",
"      Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990; 75:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/109\">",
"      Cuthbert RJ, Iqbal A, Gates A, et al. Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol 1995; 48:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/110\">",
"      Elias M, Bisharat N, Goldstein LH, et al. Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient. Eur J Clin Microbiol Infect Dis 2004; 23:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/111\">",
"      Kawasaki H, Takayama J, Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr 1996; 128:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/112\">",
"      Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152:1172.",
"     </a>",
"    </li>",
"    <li>",
"     Fetscher, S, Technau, K, Lange, W. Herpes zoster after high dose chemotherapy and autologous stem cell transplantation. In: 25th annual meeting European group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.",
"    </li>",
"    <li>",
"     Wessels, M, Nevill, T, Le, A, et al. Incidence and factors predictive of varicella-zoster virus infection following stem cell transplantation. In: 25th annual meeting European Group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/115\">",
"      Atkinson K, Meyers JD, Storb R, et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/116\">",
"      Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/117\">",
"      Webster A, Grint P, Brenner MK, et al. Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol 1989; 27:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/118\">",
"      Nakayama H, Okamura J, Ohga S, et al. Herpes zoster in children with bone marrow transplantation: Report from a single institution. Acta Paediatr Jpn 1995; 37:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/119\">",
"      Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. Blood 2006; 107:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/120\">",
"      Haque T, Thomas JA, Falk KI, et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996; 77 ( Pt 6):1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/121\">",
"      Simon M, Bartram CR, Friedrich W, et al. Fatal B-cell lymphoproliferative syndrome in allogeneic marrow graft recipients. A clinical, immunobiological and pathological study. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 60:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/122\">",
"      Nalesnik MA, Starzl TE. Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci 1994; 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/123\">",
"      Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/124\">",
"      Chadburn A, Suciu-Foca N, Cesarman E, et al. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995; 147:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/125\">",
"      Weissmann DJ, Ferry JA, Harris NL, et al. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/126\">",
"      Larson RS, Scott MA, McCurley TL, Vnencak-Jones CL. Microsatellite analysis of posttransplant lymphoproliferative disorders: determination of donor/recipient origin and identification of putative lymphomagenic mechanism. Cancer Res 1996; 56:4378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/127\">",
"      Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 1993; 99:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/128\">",
"      Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/129\">",
"      Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996; 18:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/130\">",
"      Orazi A, Hromas RA, Neiman RS, et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997; 107:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/131\">",
"      Chao NJ, Berry GJ, Advani R, et al. Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Transplantation 1993; 55:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/132\">",
"      Savoie A, Perp&ecirc;te C, Carpentier L, et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/133\">",
"      Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/134\">",
"      Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/135\">",
"      Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988; 25:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/136\">",
"      Canfield, CW, Hudnall, SD, Colonna, JO, et al. Fulminant Epstein Barr virus associated post transplant lymphoproliferative disorders following OKT3 therapy. Clin Transplant 1992; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/137\">",
"      Machado CM, Gon&ccedil;alves FB, Pannuti CS, et al. Measles in bone marrow transplant recipients during an outbreak in S&atilde;o Paulo, Brazil. Blood 2002; 99:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/138\">",
"      Azzi A, Fanci R, Ciappi S, et al. Human parvovirus B19 infection in bone marrow transplantation patients. Am J Hematol 1993; 44:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/139\">",
"      O'Reilly RJ, Lee FK, Grossbard E, et al. Papovavirus excretion following marrow transplantation: incidence and association with hepatic dysfunction. Transplant Proc 1981; 13:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/140\">",
"      Arthur RR, Shah KV, Baust SJ, et al. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 1986; 315:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/141\">",
"      Apperley JF, Rice SJ, Bishop JA, et al. Late-onset hemorrhagic cystitis associated with urinary excretion of polyomaviruses after bone marrow transplantation. Transplantation 1987; 43:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/142\">",
"      Houff SA, Major EO, Katz DA, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988; 318:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/143\">",
"      Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000; 343:1378.",
"     </a>",
"    </li>",
"    <li>",
"     Locasciulli, A, Ljungman, P, Cordonnier, C. hepatitis viruses infection complicating the management of stem cell transplantation. In: 25th annual meeting European group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/145\">",
"      Peffault de Latour R, L&eacute;vy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/146\">",
"      Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982; 96:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/147\">",
"      Espersen F, Birgens HS, Hertz JB, Drivsholm A. Current patterns of bacterial infection in myelomatosis. Scand J Infect Dis 1984; 16:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/148\">",
"      Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol 1986; 13:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/149\">",
"      Doughney KB, Williams DM, Penn RL. Multiple myeloma: infectious complications. South Med J 1988; 81:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/150\">",
"      Anaissie E, Kontoyiannis DP, Kantarjian H, et al. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 1992; 117:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/151\">",
"      O'Dwyer PJ, Spiers AS, Marsoni S. Association of severe and fatal infections and treatment with pentostatin. Cancer Treat Rep 1986; 70:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/152\">",
"      Kraut EH, Crowley JJ, Grever MR, et al. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Invest New Drugs 1990; 8:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/153\">",
"      Kraut EH, Neff JC, Bouroncle BA, et al. Immunosuppressive effects of pentostatin. J Clin Oncol 1990; 8:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/30/25066/abstract/154\">",
"      Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 80:587.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1403 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-1E93B43961-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25066=[""].join("\n");
var outline_f24_30_25066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREENGRAFTMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Candida",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Molds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Respiratory viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMMEDIATE POSTENGRAFTMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pneumocystis carinii (jirovecii) pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Human herpesviruses 6, 7, and 8",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Adenovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Enteric viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Respiratory viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Parasitic infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LATE POSTENGRAFTMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Varicella zoster virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Other viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      INFECTIONS IN SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Asplenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Hypoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Exposure to purine analogues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Environmental risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Acute management of the febrile stem cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1403\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1403|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/7/4223\" title=\"figure 1\">",
"      Infections after autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8362\" title=\"figure 2\">",
"      Infections after allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1403|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/16/7437\" title=\"table 1A\">",
"      DDx of syndromes after BMT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/7/3197\" title=\"table 1B\">",
"      DDx of syndromes after BMT II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/35/32316\" title=\"table 2A\">",
"      Pathogens following BMT-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/51/11067\" title=\"table 2B\">",
"      Pathogens following BMT-II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/26/32171\" title=\"table 2C\">",
"      Pathogens following BMT-III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/16/29965\" title=\"table 3A\">",
"      Less com pathogens after BMT-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/59/16316\" title=\"table 3B\">",
"      Less com pathogens after BMT-II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/36/19019\" title=\"table 3C\">",
"      Less com pathogens after BMT-III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/30/17900\" title=\"table 4\">",
"      BMT infections and environment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/14/16619\" title=\"table 5\">",
"      Complicating factors after BMT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43241?source=related_link\">",
"      Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=related_link\">",
"      Evaluation for infection before hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_30_25067="Senstivities of diagnostic tests for dementia";
var content_f24_30_25067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of diagnostic tests for dementia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnostic test",
"      </td>",
"      <td class=\"subtitle1\">",
"       Sensitivity, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Specificity, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mini-Mental State Exam*",
"      </td>",
"      <td>",
"       87",
"      </td>",
"      <td>",
"       82",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">",
"       Short Portable Mental Status Questionnaire*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1 sublist1\">",
"       Any dementia",
"      </td>",
"      <td class=\"sublist_other\">",
"       82",
"      </td>",
"      <td class=\"sublist_other\">",
"       92",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1 sublist1\">",
"       Mild dementia",
"      </td>",
"      <td class=\"sublist_other\">",
"       55",
"      </td>",
"      <td class=\"sublist_other\">",
"       96",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NINCDS criteria&bull;",
"      </td>",
"      <td>",
"       92",
"      </td>",
"      <td>",
"       65",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       DSM-IV criteria&bull;",
"      </td>",
"      <td>",
"       76",
"      </td>",
"      <td>",
"       80",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clinical judgment&bull;",
"      </td>",
"      <td>",
"       85",
"      </td>",
"      <td>",
"       82",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Diagnosis of dementia.",
"     <br>",
"      &bull; Diagnosis of Alzheimer disease.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25067=[""].join("\n");
var outline_f24_30_25067=null;
var title_f24_30_25068="Genetic history";
var content_f24_30_25068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient, spouse, and family genetic history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       History of congenital abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Neural tube defects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Heart defects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Orofacial clefts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Chromosomal abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Down syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mental retardation or developmental delay (eg, fragile X risk)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Advanced maternal or paternal age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Inherited diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hemoglobinopathy or thrombophilia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Muscular dystrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cystic fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Huntington's chorea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hemophilia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Metabolic disorders (eg, phenylketonuria, diabetes)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Kidney disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Deafness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Marfan syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Ethnicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Eastern European (Ashkenazi) Jews (Tay-Sachs, Canavan risk, etc)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       French Canadians or Cajuns (Tay-Sachs risk)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mediterranean (Hemoglobinopathy risk)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Asians (Hemoglobinopathy risk)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       African (Hemoglobinopathy risk)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hispanic (Hemoglobinopathy risk)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Caucasian (Cystic fibrosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Consanguinity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent pregnancy loss, stillbirth, or early infant death",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maternal metabolic disorder",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25068=[""].join("\n");
var outline_f24_30_25068=null;
var title_f24_30_25069="Allergenic herbal ingredients";
var content_f24_30_25069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potentially allergenic herbal ingredients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agnus Castus",
"       </td>",
"       <td>",
"        Allergic effects reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angelica",
"       </td>",
"       <td>",
"        Furanocoumarins, photosensitivity, contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aniseed",
"       </td>",
"       <td>",
"        Furanocoumarins, photosensitivity, contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apricot",
"       </td>",
"       <td>",
"        Contact allergy, kernels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arnica",
"       </td>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artichoke",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asafoetida",
"       </td>",
"       <td>",
"        Irritant gum, contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boneset",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cassia",
"       </td>",
"       <td>",
"        Allergic reactions, mainly contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Celery",
"       </td>",
"       <td>",
"        Furanocoumarins, photosensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chamomile, German",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chamomile, Roman",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cinnamon",
"       </td>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cornsilk",
"       </td>",
"       <td>",
"        Allergic reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cowslip",
"       </td>",
"       <td>",
"        Allergic reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dandelion",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elecampane",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Euphorbia",
"       </td>",
"       <td>",
"        Histamine potentiating properties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feverfew",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fucus",
"       </td>",
"       <td>",
"        Iodine may aggravate/trigger acne",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Garlic",
"       </td>",
"       <td>",
"        Sulphur-containing compounds, allergic reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gravel root",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guaicum",
"       </td>",
"       <td>",
"        Irritant resin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Holy Thistle",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hops",
"       </td>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrangea",
"       </td>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocotyle",
"       </td>",
"       <td>",
"        Photosensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juniper",
"       </td>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lady's Slipper",
"       </td>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meadowsweet",
"       </td>",
"       <td>",
"        Potentiation of histamine bronchospastic properties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motherwort",
"       </td>",
"       <td>",
"        Dermatitis, photosensitization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parsley",
"       </td>",
"       <td>",
"        Furanocoumarins, photosensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pilewort",
"       </td>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plantain",
"       </td>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleurisy root",
"       </td>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulsatilla",
"       </td>",
"       <td>",
"        Contact allergy, protoanemonin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rosemary",
"       </td>",
"       <td>",
"        Dermatitis, photosensitization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        St. Johns' Wort",
"       </td>",
"       <td>",
"        Photodermatitis, hypericin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tansy",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wild carrot",
"       </td>",
"       <td>",
"        Furanocoumarins, photosensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yarrow",
"       </td>",
"       <td>",
"        Sesquiterpene lactone constituents",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.284.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25069=[""].join("\n");
var outline_f24_30_25069=null;
var title_f24_30_25070="Transverse ultrasound scan of needle with echoes";
var content_f24_30_25070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse ultrasound scan of needle with echoes beneath",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse ultrasound scan of a needle, showing only a point (arrowhead) with numerous echoes beneath.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25070=[""].join("\n");
var outline_f24_30_25070=null;
var title_f24_30_25071="Parenchymal changes EUS";
var content_f24_30_25071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic parenchymal changes following pancreatic stent placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound shows hypoechoic parenchymal changes (P) surrounding the proximal end of a stricture following pancreatic duct stenting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Catalano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_30_25071=[""].join("\n");
var outline_f24_30_25071=null;
